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Resumo 
 
A tuberculose é uma doença infecciosa que afecta milhoões de pessoas em todo o mundo. Em 
2015 foram relatados 9,6 milhões de novos casos. O agente infeccioso causador da doença, 
Mycobacterium tuberculosis, desenvolveu várias resistências aos tratamentos existentes. Esta 
bactéria possui um envelope celular bastante complexo, constituído por ácidos micólicos 
interferindo na sensibilidade da bactéria aos antiobióticos hidrofóbicos. Os tratamentos 
actualmente existentes consistem em combinações de fármacos de primeira linha (isoniazida, 
rifampicina, pirazinamida e ethambutol). No entanto, surgiram estirpes resistentes a alguns dos 
fármacos administrados no tratamento dando origem a outros dois tipos da doença: tuberculose 
multi-resistente e tuberculose extensivamente multi-resistente. Nestes casos o tratamento envolve 
outro tipo de fármacos: fármacos de 2ª e 3ª linha. Estes tipos de fármacos são mais dispendiosos 
e apresentam diversos efeitos secundários.  
Nos fármacos de 2ª linha, existe um grupo de fármacos que são as fluroquinolonas. Estes fármacos 
derivam do ácido nalidíxico e contêm fluor na sua estrutura, sendo activos contra um grande 
número de bactérias. Este grupo de compostos tem como alvo enzimas envolvidos no processo 
de transcrição do DNA, processo crucial para a vitalidade da bactéria. O ácido nalidíxico é uma 
quinolona usada normalmente no tratamento de infeções urinárias causadas por bactérias. Este 
antibiótico actua através da inibição do ADN girase, um enzima fulcral no processo de transcrição 
do ADN bacteriano. 
 Estudos anteriores demonstraram que alguns ácidos fracos apresentam atividade 
antimicobacteriana contra Mycobacterium tuberculosis em virtude da sua acumulação no interior 
da célula, devido a um mecanismo de efluxo deficiente.  Sendo o ácido nalidíxico um ácido fraco, 
alterações na sua estrutura poderão melhorar as suas propriedades farmacocinéticas bem como a 
sua activida antimicobacteriana.  
Os pró-fármacos são compostos que não são biologicamente activos, ou seja, necessitam de ser 
activados através de reações químicas ou enzimáticas. Este tipo de compostos é sintetizado 
quando a substância activa possui propriedades indesejadas, como baixa absorção, degradação 
rápida por parte de enzimas, deficiente entrada nas células das micobactérias, entre outras.  
Na preparação de um fármaco contra a tuberculose, é necessário que este apresente boas 
propriedades de absorção, distribuição, metabolismo e excrecção, sendo ativo no local desejado 
e não tóxico contra o organismo humano. Neste sentido, é necessária a síntese de compostos 
estáveis à hidrólise por parte de enzimas, plasmáticos e hepáticos do hospedeiro, que penetrem a 
membrana celular da bacteria, portanto lipofílicos e que sejam activos contra a bactéria 
Mycobacterium tuberculosis. Para serem ativos, é necessário que os compostos sejam 
hidrolisados pelos enzimas da micobácteria, de forma a converter os pró-fármacos na sua forma 
activa. Por último, os derivados sintetizados devem apresentar níveis de toxicidade reduzidos para 
o hospedeiro.  
Uma das estratégias mais comuns na síntese de pró-fármacos é a formação de grupos éster pois 
estes grupos levam a um aumento da lipofilia do composto e consequentemente facilitam a sua 
passagem através das membranas biológicas. Estudos anteriores demonstraram que o 
Mycobacterium tuberculosis possui enzimas responsáveis pela hidrólise de ésteres.  
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Neste trabalho foram sintetizados derivados do ácido nalidíxico (1). Os derivados sintetizados são 
ésteres pois estes são mais lipofílicos, e por isso penetrarão mais facilmente nas micobactérias 
que o ácido correspondente. Para que os compostos sejam ativos, é necessário que cheguem ao 
local de acção sem sofrer alterações na sua estrutura. Assim, é necessário que estes ésteres sejam 
resistentes à hidrólise por enzimas humanos e, por outro lado, susceptíveis à hidrólise por parte 
de enzimas micobacterianos.  
 
 
 
 
 
Os ésteres sintetizados apresentam diferentes cadeias alcoxílicas (entre 2 e 14 carbonos), de forma 
a estudar o efeito da lipofilia na estabilidade e actividade destes. Na porção acilo, foi feita uma 
substituição em relação ao ácido nalidíxico de forma a verificar se aquela porção da molécula tem 
influência na actividade do composto. Pretendeu-se avaliar se a substituição do grupo C7-CH3 
pelo grupo C7-CCl3 levava a melhores resultados a nível de inibição do crescimento 
micobacteriano bem como se os compostos eram susceptíveis ou resistentes à hidrólise 
enzimática. De facto, estudos anteriores demonstram que aquela porção da molécula apresenta 
um papel crucial na actividade deste tipo de compostos. Para além de ésteres, foi sintetizado 
também um derivado do ácido carboxílico que continha apenas a substituição do grupo C7-CH3 
pelo grupo C7-CCl3, de forma a testar a sua actividade bem como para controlo de ensaios de 
estabilidade.  
Na síntese de todos os derivados, dois métodos distintos foram usados e observou-se que os 
rendimentos eram bastante diferentes entre os dois grupos de ésteres: ésteres com o grupo C7-CH3 
tiveram um rendimento de síntese acima dos 51% enquanto que ésteres com o grupo C7-CCl3 
tiveram um rendimento de síntese inferior a 35%.  
Os estudos de actividade foram realizados na estirpe H37Rv de Mycobacterium tuberculosis. 
Nestes estudos, foram analisadas as concentrações mínimas necessárias para inibição de 90% e 
de pelo menos 50% do crescimento bacteriano. Também foi analisada a percentagem de inibição 
do crescimento bacteriano para uma concentração administrada de composto de 100 µM. 
Observou-se que praticamente todos os derivados do ácido nalidíxico inibem o crescimento 
micobacteriano. Para além disso, verificou-se que os derivados com o substituinte C7–CCl3 são 
mais activos, de um modo geral, que os derivados com o substituinte C7-CH3.  
Foram realizados estudos de estabilidade em plasma humano e em tampão fosfato pH 7,4. Os 
estudos em plasma humano permitiram observar se os compostos são susceptíveis à hidrólise 
enzimática por partes dos enzimas presentes neste compartimento corporal. Os ensaios em tampão 
fosfato pH 7,4 foram realizados de forma a avaliar a estabilidade química dos compostos. 
Verificou-se que os derivados sintetizados são muito resistentes à hidrólise química, bem como à 
hidrólise enzimática. De facto, os compostos apresentam tempos de semi-vida bastante elevados 
revelando-se muito estáveis. Os resultados obtidos demonstram que os compostos sintetizados 
apresentam tempos de semi-vida superiores a 2,8 dias, no caso da hidrólise enzimática, e 7,8 dias 
no caso da hidrólise química. Para além disso, no estudo da susceptibilidade à hidrólise 
R1: CH3, CCl3 
R2: different alkoxyl chains 
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enzimática, houve compostos que não demonstraram degradação durante as 72 horas do ensaio 
em plasma humano. 
Fez-se também uma comparação entre as constantes cinéticas da hidrólise enzimática e da 
hidrólise química para avaliar se a hidrólise química tem impacto nos estudos de estabilidade em 
plasma humano. Verificou-se que para alguns compostos este tipo de hidrólise não é significativa, 
porém, em alguns deles, esta apresenta um impacto semelhante ao da hidrólise enzimática. Com 
base neste estudo, pretende-se o desenvolvimento de novos pró-fármacos com actividade contra 
a tuberculose, de modo a combater as estirpes resistentes aos tratamentos atuais.  
Neste trabalho, foi possível concluir que os derivados ésteres desenvolvidos do ácido nalidíxico 
são muito estáveis à hidrólise enzimática bem como à hidrólise química. Verificou-se que os 
derivados que apresentam o substituinte C7–CCl3 são mais activos contra a estirpe estudada do 
que os compostos que apresentam o substituinte C7-CH3. Apesar de praticamente todos os 
derivados sintetizados apresentaram actividade contra a bacteria, alterações na sua estrutura são 
necessárias de modo a aumentar a inibição do crescimento bacteriano, a menores concentrações 
administradas, mas mantendo a estabilidade à hidrólise enzimática no hospedeiro.  
No futuro mais estudos com este tipo de derivados serão necessários, tais como, ensaios de 
toxicidade, estudos de modelação, estudos em homogenato de fígado, entre outros. Para além 
disso, é necessário compreender qual o mecanismo que leva à inibição do crescimento bacteriano 
por parte dos derivados do ácido nalidíxico sintetizados. 
 
Palavras-chave: Tuberculose, Ácido nalidíxico, Pró-fármacos, Estabilidade, Actividade 
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Abstract 
 
Tuberculosis is one of the most prevelent diseases in the world with high rates of incindence and 
mortality. Mycobacterium tuberculosis, the causative agent of tuberculosis, is one of the leading 
bacterial cause of infection. There are several treatment regiments available to treat 
Mycobacterium tuberculosis but the development of new strains and co-infection with HIV led 
to the need of new antibiotics to treat this pathogen. One of the antibiotics to treat multidrug 
resistant and extensively drug resistant tuberculosis are fluoroquinolones. These drugs are 
fluorinated nalidixic acid derivatives and are active against a broad spectrum of bacteria.  
Nalidixic acid is a quinolone used in the treatment of urinary tract infections caused by bacteria. 
This drug inhibitis DNA gyrase, an enzyme with an important role in bacterial transcription. Many 
organic acid drugs have small half lives, high protein binding and difficulties in celular 
penetration. In order to test if we could obtain derivatives with better activity/improved 
pharmacokinetics several ester derivatives (1) were synthesized.These derivatives will be 
converted inside the bacterial cell to their correspondent acids. In order to be effective, these 
compounds need to be resistant to hydrolysis by human enzymes, but must be hydrolyzed by the 
mycobacterial enzymes.  
 
 
 
 
 
 
 
Almost all of the synthesized derivatives have shown antibacterial activity against M. tuberculosis 
H37Rv strain. Besides that, it was shown that derivatives containing the C7-CCl3 group instead of 
a C7-CH3 group inhibit more the bacterial growth.  
Stability assays were performed in human plasma and phosphate buffer pH 7.4 in order to evaluate 
enzymatic and chemical hydrolysis, respectively. With these assays, it was possible to observe 
that all the studied compounds have a good stability, being resistant to the action of the enzymes 
in human plasma. Besides that, it is possible to conclude that the synthesized compounds are also 
very resistant to chemical hydrolysis in phosphate buffer pH 7.4.  
In the present work it was possible to conclude that nalidixic acid derivatives are very stable to 
enzymatic and chemical hydrolysis. It was also observed that almost all the synthesized 
compounds are active against Mycobacterium tuberculosis and changes in the acyl structure lead 
to a higher inhibition  of bacterial growth. Although, further changes in the structure can probably 
improve further the activity of the compounds while keeping the high stability to host enzymatic 
hydrolysis. 
Keywords: Tuberculosis, Nalidixic acid, Prodrugs, Stability, Activity 
R1: CH3, CCl3 
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1. Introduction 
 
 Tuberculosis 
 
1.1.1 Epidemology 
 
Tuberculosis (TB) is a major global health problem that infects nearly one-third of the worlds 
population1. In 2014, there were an estimated 9.6 million new TB cases and 1.5 million TB deaths (1.1 
million among HIV-negative persons and 0.4 million among HIV-positive persons)2. In figure 1 is 
shown the estimated TB incidence rates in 2014 and since this number and the number of TB deaths are 
unacceptable there is an emergence to find new alternatives for treatment2. 
 
Figure 1. 1 - Estimated TB incidence rates in 20142. 
 
1.1.2 Disease Characterization 
 
TB in an infectious disease caused by Mycobacterium tuberculosis (M. tuberculosis). The infection 
starts usually by the inhalation of droplet nuclei (1-5 µm in diameter particles) containing M. 
tuberculosis, expectorated when patients with active TB cough. The inhaled droplet nuclei avoid 
defenses of the bronchi due to their small size and penetrate into terminal alveoli of the lungs where 
they are engulfed by non-specifically activated alveolar macrophages, lung macrophages and dendritic 
cells. If the macrophages are unable to destroy mycobacteria, they continue to multiply until the 
macrophages rupture. The released organisms are subsequently ingested by inactivated blood 
macrophages that are attracted to the lung by chemotactic factors3,4. In the lungs, M. tuberculosis can 
also infect endothelial cells, M cells and type 1 and 2 epithelial cells, which means that M. tuberculosis 
can infect non-phagocytic cells also3. 
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In the initial phase of the infection, M. tuberculosis internalized by macrophages and dendritic cells 
replicates intracellularly and immune cells, infected with mycobacteria, can cross the alveolar barrier 
and cause systemic dissemination5.  
The typical pattern of TB occurs in four stages. The first stage occurs in 3-8 weeks and corresponds to 
the implementation of inhaled mycobacteria in alveoli. This is followed by the dissemination through 
the lymphatic circulation to the regional lymph nodes in the lungs which results in the formation of the 
primary complex. In the second stage, the mycobacteria circulate through the bloodstream to other 
organs. This stage occurs in the ensuing approximate 3 months and some patients suffer fatal disease 
during this time. The third stage can occur at any time up to two years of infection and is marked by 
severe chest pain and inflammation of the pleural surface. The final stage consists in the resolution of 
the primary complex and can take several years and, in some cases, extrapulmonary disease can become 
manifest during this time6. 
 
1.1.3 Mycobacterium tuberculosis 
 
Mycobacterium is a bacteria genus responsible for several diseases, such as TB and leprae. They are 
acid-fast bacilli, aerobic obligate, immobile and with a cell wall rich in lipid content7.  
The scientific classification is: 
Kingdom: Bacteria 
Phylum: Actinobacteria 
Class: Actinobacteria 
Order: Corynebacterineae  
Family: Mycobacteriaceae 
Genus: Mycobacterium8 
 
These bacteria are divided in 2 groups: Non-tuberculous mycobacteria (NTM) and Mycobacterium 
tuberculosis complex (MTC). The NTM species are ubiquitous in nature, they are considered 
opportunistic pathogens and several species are associated with human diseases9. Species like M. avium, 
M. smegmatis and M. ulcerans belong to this group10,11.  In contrast, MTC is always considered pathogen 
and this group includes: M. tuberculosis, M. bovis and M. caprae10,12. 
The most pathogenic bacteria of this genus are M. tuberculosis, that causes tuberculosis, M. leprae that 
is the causative agent of leprosy and M. ulcerans, that causes ulcer, a serious superficial infection4. M. 
tuberculosis grows very slowly and has a complex cell envelop that is constituted with mycolic acids13,14. 
Mycolic acids are very long-chain branched fatty acids attached to the cell wall. They are an important 
determinant of fluidity of the cell wall and they are also related to the sensitivity of the mycobacteria 
species to hydrophobic antibiotics13,15. The generation time of M. tuberculosis in infected animals is 
typically 24h. The state of dormancy in which the bacillus remains inactive within infected tissue results 
from the action of the cell-mediated immune response that can’t eradicate the infection16. In order to 
prevent the growth of M. tuberculosis during persistent infections, the strategy used by the host consists 
in forming granulomas (aggregates of immune cells around infected tissues)17. The mycobacteria can 
stay in this state of dormancy for decades and later a failure of the immune system may permit their 
revival and the activation of the disease18.  
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There is no simple answer to what makes M. tuberculosis virulent because this bacteria does not have 
classical virulence factors like other bacterial pathogens e.g. produced toxins, so it is still necessary to 
find factors that are important for the progression of TB and therefore to a better understanding of this 
disease19,20. There is still limited knowledge of how M. tuberculosis causes disease but so far the standard 
terms “mortality” and “morbidity” have been used for a description of M. tuberculosis virulence and 
then it is important to understand the pathogenesis associated with TB20. 
 
1.1.4 Treatment 
 
The current recommended treatment of TB consists in a drug combination. Treatment requires a 
minimum of 6 months duration in 2 phases: 2 months of 4 first-line drugs (isoniazid, rifampicin, 
pyrazinamide and ethambutol) in the intensive phase followed by 4 months of isoniazid plus rifampicin 
in the continuous stage21,22.  
Improper prescriptions and patient noncompliance has led to the emergence of new strains of M. 
tuberculosis resistant to some or all current antitubercular drugs23. Multidrug resistance tuberculosis 
(MDR-TB) is defined as tuberculosis resistant to isoniazid and rifampicin and is associated with high 
death rates of 50% to 80%23,24. Treatment regiments of MDR-TB include at least 4 second-line drugs 
and total duration therapy can go up to 28 months21. Extensively drug-resistance tuberculosis (XDR-
TB) is another type of resistant TB, that is resistant to isoniazid, rifampicin, one fluroquinolone and to 
at least one of the three injectable second-line drugs that is associated with high mortality rates, takes 
substantially longer to treat than MDR-TB and requires the use of third-line anti-TB drugs, which are 
expensive and often with more side effects than first-line and second-line drugs21.  
In table 1.1 is presented some of the drugs used nowadays in the treatment of TB.   
 
Table 1. 1 - Drugs used in TB treatment21,25–28. 
Drug Class Administration Effect 
INH 1st line Oral Inhibits mycolic acid 
synthesis 
RIF 1st line Oral Inhibits transcription 
PZA 1st line Oral Acidifies cytoplasm 
EMB 1st line Oral Inhibits lipids 
biosynthesis 
STM 2nd line Injectable Inhibits protein 
synthesis 
CAP 2nd line Injectable Inhibits protein 
synthesis 
AMI 2nd line Injectable Inhibits protein 
synthesis 
KAN 2nd line Injectable Inhibits protein 
synthesis 
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Drug Class Administration Effect 
OFX 2nd line Oral 
Inhibits DNA 
supercoiling 
CYC 2nd line Oral 
Inhibits 
peptidoglycan 
synthesis 
CFZ 3rd line Oral 
Interact with 
bacterial DNA 
AMX/CLV 3rd line Oral 
Inhibition of β-
lactamase 
IPM/CLN 3rd line Injectable 
IPM – Inhibition of 
β-lactamase 
CLN – Inhibition of 
enzyme responsible 
for degradation IPM 
INH – isoniazid; RIF – rifampicin; PZA – pyrazinamide; EMB – ethambutol; STM – 
streptomycin; CAP – capreomycin; AMI – amikacin; KAN – kanamycin; OFX – ofloxacin; 
CYC – cycloserine; CFZ – clofazimine; AMX/CLV – amoxicillin plus clavulanate; 
IPM/CLN – imipenem plus cilastatin. 
 
1.1.5 Fluoroquinolones 
 
Fluoroquinolones (FQ), fluorine-containing nalidixic acid derivatives (Figure 1.2), are a group of 
compounds that target DNA gyrase and DNA topoisomerase II and have a broad-spectrum of 
antimicrobial activity21,29. These compounds are recommended and widely used in the treatment of 
bacterial infections of the respiratory, gastrointestinal, and urinary tracts, as well as sexually transmitted 
diseases and chronic osteomyelitis.  It has been shown that FQ can also penetrate into macrophages and 
have bactericidal activity there29. Besides that, FQ have shown potent activity against M. tuberculosis 
and are used as second-line drugs in TB therapy30,31. 
 
Figure 1. 2 - Four generations of quinolones. Ciprofloxacin, levofloxacin and moxifloxacin are FQ. Scaffolds are 
colored black and peripheral chemical modifications are colored red32. 
 
Ciprofloxacin (CIP), an inhibitor of DNA gyrase, is used in the most potent fluoroquinolone and is 
active against a broad range of bacteria and the most susceptible are aerobic gram-negative 
bacilli33,34.CIP was the first fluoroquinolone indicated for infections outside the urinary tract and was 
considered a major advance in therapy for aerobic gram-negative infections. However, CIP was noted 
to have poor activity against anaerobes35. This drug can also interact with a number of drugs, some 
herbal and natural supplements, and certain thyroid medications34. 
Levofloxacin (LEV) is an isomer of ofloxacin (used in treatment of MDR-TB) and has increased in vitro 
antibacterial activity against a variety of bacteria including anaerobes36. LEV is also used in the 
treatment of MDR-TB if the strain is susceptible or if the agent is thought to have efficacy31. The mode 
of action of this drug is the inhibition of DNA gyrase and DNA topoisomerase II37.  
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Moxifloxacin (MOX) is synthetic fluoroquinolone antibiotic agent used in the treatment of sinus and 
lung infections. The bactericidal action of these drugs results from inhibition of DNA gyrase and DNA 
topoisomerase II38. MOX is also a second-line drug and is the most potent fluoroquinolone used in TB 
treatment although is less active than isoniazid (first-line drug)31,39.  
 
 
1.1.6 Nalidixic Acid 
 
Nalidixic acid (NAL) (figure 1.3) was the first member of the quinolone family of antibacterial agents 
synthesized and it’s used in the treatment of urinary tract infections caused my susceptible gram-
negative microorganisms40,41. NAL is administrated orally, is rapidly absorbed from the gastrointestinal 
tract and has a bioavailability of approximately 96%. NAL metabolism is hepatic and 30% of the 
administrated dose is converted to the active metabolite, hydroxynalidixic acid (Figure 1.4)42.  
 
 
 
 
 
 
 
NAL is an antibiotic that inhibits DNA gyrase, an enzyme that catalyses the negative supercoiling of 
DNA, that is essential for DNA replication, transcription and recombination43,44. This enzyme is 
constituted by two A subunits and two B subunits, encoded by gryA and gryB, respectively44.Quinolone 
sensitivity is controlled by subunits A, which contain the breakage-reunion active site while subunits B 
promote ATP hydrolysis, needed for energy transduction23,44.    
It was shown that fluoroquinolones had the potential to reduce the duration of therapy in TB murine 
models21.  NAL and other quinolones were previously tested in M. tuberculosis with a mutation in gryA 
and have shown poor DNA cleavage stimulation44. These mutations occur in a conserved region that is 
called quinolone resistance-determining region (QRDR) of the gyrA and gyrB genes. Mutations within 
the QRDR are associated with quinolones resistance29. 
 
 Prodrugs 
 
Prodrugs are compounds that are not biologically active and have to be transformed into active products 
by enzymatic or chemical reactions45. The active compounds have undesirable properties that may 
become pharmacological, pharmaceutical or pharmacokinetic barriers in clinical drug application. Using 
drug derivatization with retention of the desirable therapeutic activity has an important role on 
improving drug efficacy46. Optimizing drug activity is a two-dimensional problem because the activity 
at the target is essential but is just as important as the efficient delivery of the agent in that same target47. 
Figure 1. 3 - NAL structure. Figure 1. 4 - Hydroxynalidixic acid 
structure. 
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Prodrugs can be applied to achieve increased chemical or metabolic stability, higher water solubility or 
higher solubility in lipid membranes, reduced toxicity, improved oral or local absorption45. The main 
objectives of prodrugs are: 
 Modification of drug pharmacokinetics; 
 Longer action; 
 Decrease in toxicity and side-effects; 
 Increase in selectivity; 
 Resolution of formulation problems, such as stability, solubility and organoleptic properties48. 
Prodrugs can be classified in two main classes: carrier-linked prodrugs and bioprecursor prodrugs. In 
carrier-linked prodrugs, the active compound is temporary linked to a carrier through a bioreversible 
covalent linkage. Once in the body, the carrier-linked prodrug undergoes biotransformation, releasing 
the drug and the carrier. The carrier should be nonimmunogenic, easy to synthesize at a low cost, stable 
under the conditions of prodrug administration and undergo biodegradation to nonactive metabolites. 
This class includes a group of prodrugs called co-drugs that are prodrugs with two pharmacologically 
active agents coupled together into a single molecule. Bioprecursors are prodrugs that result from a 
molecular modification of the active compound itself. The bioprecursor prodrug is transformed 
metabolically or chemically by hydration, oxidation or reduction into the active agent49. 
Prodrugs can also be classified in two another types, depending on the site of conversion to the active 
metabolite: Type I prodrugs are metabolized intracellularly (Type IA, at the cellular targets of their 
therapeutic action and Type IB, by metabolic tissues), whereas Type II prodrugs are metabolized 
extracellularly (Type IIA, in the milieu of the gastrointestinal fluid; Type IIB, in the circulatory system 
and/or other extracellular fluid compartments and Type IIC, near or inside therapeutic target/cells)49,50. 
Some of the first- and second-line agents used in the treatment of TB are prodrugs (for example, 
isoniazid and pyrazinamide). These antimycobacterial prodrugs can be divided in two main groups 
depending on their mechanism of action: mycobacteria bioactivated and host bioactivated. The 
mycobacteria bioactivated prodrugs have increased bioavailability and solubility, and decreased 
toxicity. The main benefits of host-bioactivated drugs are: increased bioavailability and therapeutic 
effectiveness; improved solubility, chemical stability; increased organ/tissue-selective delivery of the 
active agent and decreased toxicity. However, the main problem of antimycobacterial prodrugs, already 
used in TB treatment, is the emergence of strains resistant to prodrugs due to mutations in the gene 
encoding the activator50. 
 
1.2.1 Esters as Prodrugs 
 
The prodrug strategy is one of the most promising approaches to enhance the therapeutic efficacy of 
pharmacologically active agents by optimizing the absorption, distribution, metabolism, excretion and 
toxicity (ADMET) properties of the parent drugs. This is a faster strategy than searching for entirely 
new therapeutic agents with suitable ADMET characteristics50.  
Prodrug design is used to improve the active drugs and some of the most common functional groups, 
such as carboxylic, hydroxyl, amine, phosphate and carbonyl are transformed in esters, carbonates, 
carbamates, amides and phosphates.51 
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The features of an ideal prodrug include: hydrolysis resistance during absorption; weak or no activity; 
aqueous solubility; good permeability through cells; chemical stability at different pH and kinetics that 
allow the release of the parental drug. Among the chemical bonds used to link the parental drug and 
carrier, esters have proven to be promising due to their amenability to hydrolysis both in vivo and in 
vitro52. 
Esters of active agents with carboxyl, hydroxyl or thiol functionalities are the most commonly used 
prodrugs because these prodrugs enhance the lipophilicity, thus the passive membrane permeability, and 
decrease  the water solubility by masking charged groups49,51. An ideal ester prodrug should have 
chemical stability across pH range, high aqueous solubility and exhibit good transcellular absorption 
phase49.  
 
1.2.2 Chemical Hydrolysis  
 
Carboxylic acid derivatives hydrolysis can be catalysed by acids or bases. The hydrolysis mechanisms, 
in both acid- and base-promoted, involve a nucleophilic addition-elimination at the acyl carbon53. 
 
Figure 1. 3 - Scheme of chemical hydrolysis of carboxylic derivatives (esters and amides). (a) acid catalysis (b) base 
catalysis54. 
In acid catalysis (Figure 1.5a), the first step is the protonation of the ester carbonyl to make it more 
electrophilic. Then, the water oxygen functions as the nucleophile attacking the electrophilic carbon in 
the C=O, creating the tetrahedral intermediate. The oxygen from the water is deprotonated to neutralise 
the charge and the XH group is protonated to convert it into a good leaving group: the carboxylic acid 
product is obtained and the acid catalyst is regenerated53–55. 
In base hydrolysis (Figure 1.5b), the hydroxy nucleophile attacks at the electrophilic carbon of the ester 
C=O, creating the tetrahedral intermediate. Then, the intermediate expels an alkoxyl ion, leading to the 
carboxylic acid. After, transfer of a proton leads to the products of the reaction53,55. 
 
1.2.3 Enzymatic Hydrolysis 
 
The enzymatic hydrolysis is a common hydrolysis reaction that is catalyzed by an enzyme. Enzymatic 
hydrolysis is more efficient than chemical hydrolysis due to the decrease in the Gibbs energy of the 
transition state54. Esters and amides, endogenous or exogenous, are one of the major substrates for 
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hydrolases, enzymes of class 3 that catalyze the attack to functional groups by water molecules. 
Hydrolases have three catalytic features at the active site that accelerate the rate of hydrolysis (Figure 
1.6)54,56.  These catalytic sites are: an electrophilic component, which increases the polarization of the 
carbonyl group in the substrate (Z+); a nucleophile to attack the carbonyl C-atom, leading to the 
formation of a tetrahedral intermediate (Y:) and a proton donor to transform -OR’ and –NR’R’’ into 
better leaving groups (H-B)54. 
 
Figure 1. 4 - Catalytic groups of hydrolases involved in ester and amide bond hydrolysis54. 
Based on the structures of their catalytic sites, hydrolases can be divided in five classes: serine 
hydrolases, threonine hydrolases, cysteine hydrolases, aspartic hydrolases and metallohydrolases54. 
Hydrolases have different substrates such as: peptides, ethers, esters, glycosylases, acid anhydrides and 
halide bonds57.   
 
 Esterases 
 
Esterases are enzymes that catalyze the cleavage and formation of ester bonds. These enzymes belong 
to hydrolases class of enzyme, EC 3 and can act as hydrolyses when catalyzing the cleavage of ester 
bonds57,58. Within the ester formation bonds esterases can catalyze three types of reactions: 
esterifications, interesterification and transesterification reactions with good chemo-, region- and/or 
enantioselectivity58. Esterases are subdivided in the type of reaction they catalyze: 
 Carboxylic ester hydrolases (EC 3.1.1); 
 Thioester hydrolases (EC 3.1.2); 
 Phosphatases (EC 3.1.3); 
 Phosphodiester hydrolases (EC 3.1.4); 
 Triphosporic monoester hydrolases (EC 3.1.5); 
 Sulfatases (EC 3.1.6); 
 Diphosphoric monoesterases (EC 3.1.7); 
 Phosphoric triester hydrolases (EC 3.1.8); 
 Exonucleases (EC 3.1.11-16); 
 Endonucleases (EC 3.1.21-31)57. 
The major carboxylic ester hydrolases classes are carboxylesterases (EC 3.1.1.1, carboxylic-ester 
hydrolase) and carboxylesterases (EC 3.1.1.3, triacylglycerol hydrolases)59. Carboxylesterases catalyze 
the hydrolysis of a wide variety of substrates including esters, amides and carbamates (endogenous or 
exogenous)60. These enzymes catalyze hydrolysis of esters, by the water, resulting in alcohol and 
carboxylate61. The three-dimensional structure of carboxylesterases show the characteristic α/β-
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hydrolase fold59 (Figure 1.7). In this structure, each parallel β-segment is attached to its neighbour by 
an α-helical segment56. The catalytic triad is composed of serine-aspartic acid-histidine (Ser-Asp-His) 
(Figure 1.7) and usually a consensus sequence glycine-x-x-leucine (Gly-x-x-Leu motif, where x can be 
any amino acid residue) is around the active site. The mechanism for ester hydrolysis is based in of four 
steps: first, the substrate is bound to the active serine, yielding a tetrahedral intermediate stabilized by 
the catalytic His and Asp residue. Then, the alcohol is released and an acyl-enzyme complex is formed. 
Next, attack of water forms again a new tetrahedral intermediate, which after resolution yields the acid 
and free enzyme59.  
 
Figure 1. 5 – Scheme of the α/β-hydrolase fold. β-Sheets (1-8) are shown as blue arrows, α-helices (A-F) as red columns 
and the relative positions of the amino acids residues of the catalytic triad are indicated as orange circles59.  
Carboxylesterases are widely present throughout the body (e.g., intestine, brain, skin, etc.) with their 
highest activity being in the liver. These esterases act also as an effective biological barrier to limit the 
distribution of substrates that might be toxic and induce their elimination by turning them into polar 
molecules. Ester prodrugs are intentionally designed to be activated by these esterases since most 
compounds will be detoxified by them62.  
 
1.3.1 Esterases of Human Plasma 
 
Human plasma esterases have an important role in drug metabolism. These enzymes participate in 
activation of ester prodrugs, inactivation of drugs and detoxify natural and synthetic ester-containing 
poisons63.  
The human plasma has three esterases groups: 
 Butyrylcholinesterase (EC 3.1.1.8); 
 Paraoxonase (EC 3.1.8.1); 
 Acetylcholinesterase (EC 3.1.1.7)63. 
Besides this three groups, there is a very important and abundant protein in the human plasma with ester 
hydrolytic capacity: albumin63. 
Paraoxonases are called “A-esterases” whereas butyrylcholinesterase and acetylcholinesterase are called 
“B-esterases”64. 
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Butyrylcholinesterase (BChE) is also known as pseudocholinesterase, non-specific cholinesterase or 
simply cholinesterase. This enzyme acts on butyrylcholine and acetylcholine. BChE has higher activity 
in liver, intestine, lungs, heart and kidney. Serum BChE is synthesized in liver and secreted into plasma, 
where it has higher activity65,66. BChE has also an important role as detoxification enzyme because it 
can hydrolyse compounds with carboxylic or phosphoric acid ester groups. Therefore, this enzyme can 
hydrolyse compounds like: succinyldicholine (neuromuscular blocking drug); cocaine; aspirin; heroin 
and others65. 
Paraoxonase is an enzyme family with three members: paraoxonase 1(PON1), paraoxonase 2 (PON2) 
and paraoxonase 3 (PON3). These esterases are capable of hydrolysing organophosphates as well as 
aromatic esters64. PON1 and PON3 can be found in the cholesterol-carrying particles HDL and can 
inhibit lipid oxidation in LDL whereas PON2 is found in many tissues67. Only PON1 is present in human 
plasma. PON1 is a proefficient esterase toward several synthetic substrates whereas PON2 and PON3 
exhibit high lactonase activity64. 
Acetylcholinesterase (AChE) or “true cholinesterase” is known to be abundant in brain, muscle and 
erythrocyte membrane being present in negligible amounts in human plasma63,65. Like BChE, AChE 
belongs to the α/β hydrolase-fold family66. The main function of AChE is hydrolysis of the 
neurotransmitter acetylcholine at cholinergic synapses and it is one of the fastest enzymes known65.  
Albumin, most known as human serum albumin (HSA), is the most soluble protein in the body (about 
4% in serum) and the most prominent protein in plasma. This protein is responsible for a lot of multiple 
functions in the body, including the maintenance of blood osmolarity, acting as an antioxidant and 
serving as a solubilising agent and carrier for many endogenous and exogenous compounds68. HSA has 
also the capacity of transporting different substances including fatty acids, hormones, enzymes, dyes, 
trace metals and drugs. Substances that are toxic in the unbound or free state are generally not toxic 
when bound to HSA. These properties give to HSA the capability to regulate the extracellular 
concentration of numerous endogenous as well exogenous administrated substances69. HSA does not 
have an enzyme commission number which means that this protein is considered to be inert, without 
any catalytic activity. However, it was proven that HSA has esterase activity. The active site of this 
protein is one tyrosine residue (Tyr411). Although the enzymatic activity of a single molecule of HSA 
is low, the concentration of this protein is very high, which means that HSA has a significant 
contribution to drug metabolism63.  
In the human plasma, these four proteins types of esterases are the only ones that have contribution on 
ester hydrolysis.  
 
1.3.2 Mycobacterial Esterases  
 
As described before, M. tuberculosis has a complex cell envelope with mycolic acids, suggesting that 
there must be a large number of enzymes involved in lipid metabolism70. Besides, it was discovered the 
existence of lipid inclusions in mycobacteria cytoplasm which indicates the presence of lipolytic 
enzymes71. In fact, after the whole genome sequence of this bacteria being studied by the Sanger Center 
and the Institut Pasteur, in 1998, it showed at least 250 enzymes related to lipid metabolism including 
extracellular secreted enzymes, integrated cell wall enzymes and intracellular lipases/esterases70. From 
the genome annotation of M. tuberculosis, it has been concluded that 24 genes encode lipolytic enzymes. 
These proteins have been classified “Lip family” (LipC to LipZ)72,73. However, this classification is only 
based on the presence of the consensus sequence Gly-x-Ser-x-Gly, which is characteristic of the 
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members of the α/β hydrolase family. This classification does not allow the distinction between lipases 
and esterases but Blast analysis has shown that the “Lip family” is composed of both lipases and 
esterases17. Esterases preferentially break ester bonds of shorter chain fatty acids and lipases catalyze 
lipid hydrolysis, which means that lipases display a much broader substrate range than esterases72. A 
fundamental difference between esterases and lipases is their ability to act on solubilised substrates. 
Esterases act on water-soluble molecules and lipases are highly efficient at hydrolysing molecules 
aggregated in water, such as an emulsion or a micellar solution74.  
Analysis of the M. tuberculosis genome revealed the existence of some carboxylesterases that are 
responsible for ester hydrolysis. The carboxylesterases identified are members of the “Lip family”: 
Rv3487c (LipF) and Rv1399 (LipH)75,76. LipF belongs to the α/β hydrolase-fold family and hydrolyze 
efficiently short chain esters. The active site of many α/β hydrolases is constituted by a catalytic triad 
with serine as the nucleophile, histidine as a proton donor and aspartate or glutamate forming the charge-
relay network. In LipF, the potential catalytic triad is: Ser90-Glu189-His219, which means that it 
contains a glutamate residue (Glu) instead of aspartate residue. The aspartate or glutamate residue is 
strongly bonded to the nitrogen into histidine residue, stabilizing the protonated positively charged 
protonated, the correct tautomer and the correct conformation of His76. Like LipF, LipH belongs to the 
α/β hydrolase-fold family. This enzyme hydrolyses efficiently short-chain triacylglycerols and vinyl 
esters and has no detectable activity against emulsified substrates. The catalytic triad of LipH: Ser162-
Asp260-His29075.  
In 2010, Guo et. al demonstrated that Rv0045c is an esterase of M. tuberculosis, involved in ester/lipid 
metabolism70. Compared with LipF and LipH, Rv0045c has shown no sequence identity in a multiple 
sequence alignment. Although, this alignment showed that the active site (Gly-x-Ser-x-Gly sequence 
motif) characteristic of hydrolases is highly conserved and the main catalytic residues are Ser89, 
Asp113, Ser206 and His234, usually present on the catalytic triad of esterases. Like LipF and LipH, 
Rv0045c can efficiently catalyse short chain ester substrates70.  
 
 The Aim of the Thesis  
 
In the present work, the main objective was to synthesize nalidixic acid (NAL) derivatives with activity 
against M. tuberculosis. The pretended derivates are long chain esters because they can have an adequate 
plasma stability and can be activated by mycobacterial esterases77. Besides that, NAL is a weak acid and 
it was previously discovered that M. tuberculosis is susceptible to weak acids, suggesting a relation 
between antimycobacterial activity and pKa of acids78.  
So, different nalidixic acid derivatives were synthesized with modifications on carbon C7 (R1 = -CH3 or 
–CCl3) and different alkoxyl chains (R2), as it is shown in Figure 1.8: 
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Stability studies in human plasma and phosphate buffer were also performed in order to evaluate 
enzymatic and chemical hydrolysis, respectively. The phosphate buffer assays are useful to evaluate if 
chemical hydrolysis has or not contribution to the velocity of human plasma hydrolysis because it is 
used a suspension of human plasma 80% in phosphate buffer. Human plasma assays are also useful to 
evaluate if the synthesized prodrugs are stable and will not degradate until they achieve the target.  
Activity studies against M. tuberculosis H37Rv strain were done in order to evaluate if compounds inhibit 
bacterial growth.  
With this work, it is pretended to have an ester of nalidixic acid or of a nalidixic acid derivative with 
slow plasma hydrolysis and activity against M. tuberculosis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 6 - NAL derivatives representation. R1 = -CH3, -CCl3; R2= different alkoxyl chain.   
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Synthesis and Structural Identification 
2. Synthesis and Structural Identification 
 
2.1 Ester Synthesis 
 
The esterification reaction is one of the most important and fundamental reactions in organic synthesis79. 
Carboxylic acids react with alcohols to form esters through a condensation reaction (Figure 2.1). 
 
 
 
 
 
Ester synthesis can be achieved in acid-catalysed reactions, that are called Fischer esterifications, or 
from alkanoyl chlorides (acyl chlorides). In Fischer esterifications (Figure 2.2), the carboxylic acid 
accepts a proton from the strong catalyst. Then the alcohol attacks the protonated carbonyl group to give 
a tetrahedral intermediate. After that, a proton is lost from one oxygen atom and gained by another one. 
The loss of a water molecule gives a protonated ester and finally the transfer of that proton to a base 
leads to the ester53.  
 
Figure 2. 2 - Mechanism of acid-catalyzed esterification53. 
 
2.1.1 Esters from Acyl Chlorides 
 
One of the best methods to synthesize esters is the reaction of acyl chlorides with alcohols (Figure 2.3). 
This reaction occurs rapidly and does not require an acid catalyst53. 
Figure 2. 1 - General reaction of ester synthesis. 
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Figure 2. 3 - General reaction of acyl chlorides synthesis with thionyl chloride53. 
Acyl halides are the most reactive of the acyl derivatives; the best synthetic route to an ester is synthesis 
of an acyl halide, chloride as an example, from the carboxylic acid first and then the conversion of the 
acyl chloride to the ester, through the reaction with an alcohol.  
The reagent used to form acyl chlorides was thionyl chloride because it reacts with carboxylic acids to 
give acyl chlorides in good yield (Figure 2.4): 
 
 
 
 
Figure 2. 4 - Mechanism of acyl chlorides synthesis using thionyl chloride53. 
These reactions involve nucleophilic addition-elimination by a chloride ion on a highly reactive 
intermediate, a protonated acyl chlorosulfite. This intermediate contains even better acyl leaving group 
than the acyl chloride product53 
 
2.2 Synthesis of Nalidixic Acid Esters 
 
In the present work, the main objective was to synthesize two libraries of NAL esters (Figure 2.5). 
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Figure 2. 5 – Libraries of NAL esters. (a) library 1; (b) library 2.  
To synthesize the esters of these different libraries, two methods were performed. The first method 
(method A), was used to synthesize the first library of compounds (Figure 2.5a), esters with different 
alkoxyl chains with the C7 methyl group on the heteroaromatic acyl group. To synthesize the second 
esters library, with different alkoxyl chains with the trichloromethyl group on the C7 heteroaromatic acyl 
portion (Figure 2.5b), method B was used. Method A was based on the description done by Sachdeva 
et. al. in 201580 and Method B was based on the description done by Cynamom et. al. in 199581. 
Method A 
To 1 equivalent (eq.) of NAL in a round bottom flask, 19.2 eq. of thionyl chloride were added and the 
flask was kept in fuming chamber aside for 15 min. Later 34.4 eq. of the alcohol were added to the 
solution drop by drop and mixed thoroughly after each addition. Then the reaction was kept under reflux 
during 1 hour (h) (Figure 2.6)80. 
 
Figure 2. 6 – Scheme of ester synthesis by method A. 
 
Method B 
To 1.2 eq. of NAL in a round bottom flask, 16.5 eq. of thionyl chloride were added and this reaction 
was kept under reflux for 2h. The acyl chloride was isolated as solid residue by evaporation of the thionyl 
chloride in excess under vacuum on a rotary evaporator. Meanwhile, 1.5 eq. of NaH were added to 1 eq. 
of alcohol to prepare its alkoxide. Then, the alkoxide was added to the acyl chloride solid residue 
previously dissolved in dried dichloromethane and this reaction was kept under reflux to synthesize the 
ester (Figure 2.7). The reaction was followed by thin layer chromatography. 
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Figure 2. 7 - Scheme of ester synthesis by method B. 
 
 
 
 
2.2.1 First library of Esters 
 
The first esters library was synthesized by method A. These esters have different alkoxyl chain, 
ranging from 2 until 14 carbons length.  
 
Table 2. 1 - First library of NAL esters. 
 
 
 
 
 R Reflux (h) Yield (%) Description 
2 C2H5 1 65 White solid 
3 C4H9 1 68 White solid 
4 C6H13 1 59 White solid 
5 C9H19 1 51 White solid 
6 C10H21 1 60 White solid 
7 C11H23 1 65 White solid 
8 C12H25 1 66 Yellow solid 
9 C14H29 1 63 Yellow solid 
10 CH(CH3)C7H15 1 79 Yellow solid 
 
In the first library of compounds, 9 different esters were synthesized with different alkoxyl chains from 
2 to 14 carbons length and they were obtained with a range of yields from 51% to 79%. The esters 2-9 
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have linear alkoxyl chains and the ester 10 has a linear alkoxyl chain of 8 carbons with one ramification 
(methyl group) in the first carbon of the chain (figure 2.8).  
 
Figure 2. 8 – Structure of compound 10. 
 
2.2.2 Seconds Library of Esters 
 
The second esters library was synthesized by method B. These esters have different alkoxyl chains, from 
4 until 14 carbons length. 
 
 
 
 
Table 2. 2 - Second library of NAL derivatives. 
 
 
 
 
 R Reflux (h) Yield (%) Description 
1a H 
overnight 100 Brown solid 
3a C4H9 
18 21 White solid 
5a C9H19 
19 5 White solid 
6a C10H21 
11 5 Yellow solid 
7a C11H23 
11 15 Yellow solid 
8a C12H25 
40 15 Yellow solid 
9a C14H29 
16 35 Yellow solid 
10a CH(CH3)C7H15 
33 20 Yellow oil 
 
In the second ester library group, 7 different esters were synthesized and the yields obtained were very 
low, ranging from 5% to 35%. This may be due to the excess of acid in this method instead the alkoxide 
(like in method A, but with the alchohol).  
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This method starts with 2h of reflux of the acid with thionyl chloride. This step led to the synthesis of 
the acyl chloride and also the chlorination of the methyl group in carbon C7 of the aromatic acyl group. 
This substitution occurs because chlorination occurs rapidly in methyl groups attached ortho or para to 
a nitrogen atom in a multi-heteroatom ring82.  
Compound 1a is not an ester, is a carboxylic acid derivative of nalidixic acid. This compound was 
synthesized as a control for the stability assays. Like the synthesis of the esters of this library, nalidixic 
acid was kept under reflux with thionyl chloride for 2 hours. Then, the excess of thionyl chloride was 
evaporated and water was added until the carboxylic acid was formed.  
The esters obtained through this method have linear alkoxyl chains except the compound 10a which has 
a linear alkoxyl chain of 8 carbons with one ramification on the first carbon of the chain (Figure 2.9). 
 
 
 
Figure 2. 9 - Structure of compound 10a. 
 
 
2.3 Structural Identification of Synthetized Esters 
 
2.3.1 Nuclear Molecular Ressonance 
 
The proton (1H) and carbon (13C) NMR spectra were obtained in deuterated chloroform (CDCl3). All 
the NMR spectra of the synthesized compounds are characterized in chapter 7. 
All the signals identification have been made with the help of Heteronuclear Multiple-Quantum 
Correlation (HMQC) and Heteronuclear Multiple Bond Correlation (HMBC) and Attached Proton Test 
(APT) spectra for carbons besides the normal proton (1H) and carbon (13C) spectra, as can be seen an 
example in Appendix 1.  
 
Table 2. 3 - 1H-NMR signal (ppm) of aromatic protons and protons attached to C1’, C2’ and C1’’ in libraries 1 and 2. 
  
 
 
 
 
Compound 
Library 1 
Aromatic 
protons 
C1’-H C2’-H C1’’-H 
Library 1 Library 2 
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1 
8.91 (C2-H); 8.67 
(C5-H); 7.41 (C6-
H) 
4.63 1.55 2.75 
2 
8.65 (C5-H); 8.63 
(C2-H); 7.24 (C6-
H) 
4.49 1.50 2.66 
3 
8.63 (C5-H); 8.60 
(C2-H); 7.23 (C6-
H) 
4.48 1.48 2.65 
4 
8.57 (C5-H); 8.54 
(C2-H); 7.16 (C6-
H) 
4.41 1.42 2.59 
5 
8.57 (C5-H); 8.53 
(C2-H); 7.16 (C6-
H) 
4.41 1.42 2.58 
6 
8.65 (C5-H); 8.61 
(C2-H); 7.24 (C6-
H) 
4.33 1.49 2.66 
7 
8.65 (C5-H); 8.61 
(C2-H); 7.24 (C6-
H) 
4.48 1.49 2.66 
8 
8.65 (C5-H); 8.61 
(C2-H); 7.24 (C6-
H) 
4.48 1.49 2.66 
9 
8.57 (C5-H); 8.54 
(C2-H); 7.17 (C6-
H) 
4.41 1.42 2.59 
 
Compound 
Library 1 
Aromatic 
protons 
C1’-H C2’-H C1’’-H 
10 
8.64 (C5-H); 8.57 
(C2-H); 7.23 (C6-
H) 
4.48 1.49 2.65 
Compound 
Library 2 
Aromatic 
protons 
C1’-H C2’-H C1’’-H 
1a 
9.03 (C2-H), 8.99 
(C5-H); 8.22 (C6-
H) 
4.67 1.63 - 
3a 
8.92 (C5-H); 8.70 
(C2-H); 8.06 (C6-
H) 
4.52 1.57 - 
5a 
8.93 (C5-H); 8.71 
(C2-H); 8.06 (C6-
H) 
4.53 1.58 - 
6a 
8.93 (C5-H); 8.71 
(C2-H); 8.07 (C6-
H) 
4.36 1.58 - 
7a 
8.92 (C5-H); 8.69 
(C2-H); 8.06 (C6-
H) 
4.52 1.57 - 
8a 
8.93 (C5-H); 8.71 
(C2-H); 8.07 (C6-
H) 
4.53 1.58 - 
9a 
8.84 (C5-H); 8.62 
(C2-H); 7.98 (C6-
H) 
4.44 1.49 - 
10a 
8.91 (C5-H); 8.66 
(C2-H); 8.05 (C6-
H) 
4.52 1.58 - 
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After 1H-NMR spectra analysis, it is observed that chemical shifts of aromatic protons are different 
between the two libraries of compounds staying in general at higher positions in the second library (table 
2.3). In the first library, C5-H protons have a chemical shift between 8.57-8.65 ppm, C2-H between 8.53-
8.63 ppm and C6-H between 7.16-7.24 ppm and in the second library, C5-H protons have a chemical 
shift between 8.93-8.84 ppm, C2-H between 8.71-8.62 ppm and C6-H between 8.07-7.98 ppm. These 
differences occur due to the substitution of the methyl group hydrogens for three chlorines. The same 
fact is also observed in proton spectra of the two acids: 1 with C7-methyl and 1a with C7-chloromethyl 
groups. 
Also, when comparing each group of esters with their acid (table 2.3) it is possible to conclude that after 
ester formation, all the 1H-NMR signals of the spectra for both groups of esters have a lower chemical 
shift more evident in the signal of C2-H and an exchange between the positions of C2-H and C5-H signals 
is observed from the acid to the esters. 
Other difference between the 1H-NMR spectra of the two libraries is the existence of a singlet at 2.58-
2.66 ppm on library 1 which corresponds to the methyl group attached to carbon C7. This singlet signal 
does not exist in compounds of library 2 because the protons of the methyl group attached to carbon C7 
were substituted by three chloro atoms on the trichloromethyl group.   
Compounds 10 and 10a with a methyl group connected to carbon C1’’’ of the alkoxyl chain transforms 
this carbon in a chiral carbon, that is an asymmetric atom or stereocenter, and this fact implies that the 
two protons of the next carbon on the alkoxyl chain C2’’’ are nonequivalent and are called diastereotopic, 
as such two different signals appear in the proton 1H-NMR spectra. Therefore instead of the signal C2’’’-
H of the two equivalent protons, like on the other esters, due to the splitting with C1’’’ and C3’’’ protons 
resulting in a tt which appears as a multiplet with two protons integration, these signals will result in a 
ddt splitting appearing as two multiplet signals with one proton integration each.  
The aromatic protons C5-H and C6-H appear as duplets and the coupling constants (J) were:  
J5-6 = 8.1 Hz (library 1),  
J5-6 = 8.1-8.4 Hz (library 2),  
With the ethyl group N1-C1’H2-C2’H3 the C1’-H appears as a quadruplet and C2’-H as a triplet with a 
coupling constant: 
JC1’H-C2’H = 7.2 Hz (both groups of compounds). 
On the other hand with the alkoxyl protons the chains last carbon appears as a triplet with coupling 
constants: 
J(last carbon-H)≈ 6.9-7.8 Hz. 
And for both groups of compounds, except 10 and 10a, C1’’’-H appears as a triplet with coupling 
constants:  
J C1’’’-H’ ≈ 6.6-7.2 Hz  
Whereas in compounds 10 and 10a the protons CH3-C1’’’appear as a duplet with a coupling constant: 
J CH3-C1’’’-H = 6.3 Hz (compounds 10 and 10a).  
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The protons in the alkoxyl chains have an overlap in the protons signal being more common in the longer 
alkoxyl chains.  
 
Table 2. 4 - 13C-NMR signal (ppm) of carbons in libraries 1 and 2. 
 
 
 
 
 
 
Compounds 
Library 1 
Aromatic carbons C9 C1’ C2’ C1’’ 
2 
174.74 (C4); 162.66 (C7); 148.74 (C2); 148.58 
(C8a); 136.86 (C5); 121.51 (C4a); 121.14 (C6); 
112.48 (C3) 
165.64 46.53 15.03 24.96 
3 
174.71 (C4); 162.62 (C7); 148.68 (C2); 148.60 
(C8a); 136.86 (C5); 121.52 (C4a); 121.10 (C6); 
112.06 (C3) 
165.77 46.57 15.22 25.08 
4 
174.74 (C4); 162.63 (C7); 148.66 (C2); 148.62 
(C8a); 136.89 (C5); 121.53 (C4a); 121.11 (C6); 
112.06 (C3) 
165.72 46.57 15.21 25.08 
 
 
Compounds 
Library 1 
Aromatic carbons C9 C1’ C2’ C1’’ 
5 
174.73 (C4); 162.62 (C7); 148.66 (C2); 148.61 
(C8a); 136.89 (C5); 121.54 (C4a); 121.10 (C6); 
112.07 (C3) 
165.72 46.57 15.21 25.08 
6 
174.72 (C4); 162.62 (C7); 148.66 (C2); 148.62 
(C8a); 136.89 (C5); 121.54 (C4a); 121.10 (C6); 
112.07 (C3) 
165.73 46.57 15.21 25.08 
7 
174.71 (C4); 162.61 (C7); 148.66 (C2); 148.62 
(C8a); 136.89 (C5); 121.55 (C4a); 121.09 (C6); 
112.09 (C3) 
165.74 46.56 15.22 25.08 
8 
174.73 (C4); 162.63 (C7); 148.66 (C2); 148.61 
(C8a); 136.89 (C5); 121.54 (C4a); 121.11 (C6); 
112.07 (C3) 
165.72 46.57 15.22 25.08 
9 
174.74 (C4); 162.63 (C7); 148.66 (C2); 148.61 
(C8a); 136.89 (C5); 121.53 (C4a); 121.11 (C6); 
112.07 (C3) 
165.72 46.57 15.21 25.08 
10 
174.76 (C4); 162.54 (C7); 148.62 (C2); 148.37 
(C8a); 136.87 (C5); 121.52 (C4a); 121.02 (C6); 
112.49 (C3) 
165.07 46.52 15.19 25.06 
Compounds 
Library 2 
Aromatic carbons C9 C1’ C2’ C1’’ 
1a 
178.04 (C4); 161.52 (C7); 155.21 (C2); 149.73 
(C8a); 147.44 (C5); 139.16 (C4a); 121.89 (C6); 
110.82 (C3); 
165.85 48.56 15.09 117.84 
Library 1 
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3a 
173.69 (C4); 160.02 (C7); 149.78 (C2); 147.48 
(C8a); 139.55 (C5); 124.08 (C4a); 116.59 (C6); 
113.07 (C3) 
165.18 47.64 14.98 96.39 
5a 
171.71 (C4); 160.03 (C7); 149.74 (C2); 147.48 
(C8a); 139.57 (C5); 124.09 (C4a); 116.58 (C6); 
113.09 (C3) 
165.15 47.62 14.96 96.40 
6a 
173.74 (C4); 160.01 (C7); 149.77 (C2); 147.52 
(C8a); 139.59 (C5); 124.10 (C4a); 116.57 (C6); 
113.09 (C3); 
165.19 47.63 14.97 96.44 
7a 
173.72 (C4); 160.03 (C7); 149.68 (C2); 147.49 
(C8a); 139.56 (C5); 124.09 (C4a); 116.55 (C6); 
113.06 (C3) 
165.73 47.65 14.96 96.42 
8a 
173.86 (C4); 159.99 (C7); 149.59 (C2); 147.65 
(C8a); 139.89 (C5); 124.11 (C4a); 116.58 (C6); 
113.12 (C3) 
165.77 47.63 14.94 96.35 
9a 
173.69 (C4); 160.03 (C7); 149.75 (C2); 147.49 
(C8a); 139.57 (C5); 124.10 (C4a); 116.57 (C6); 
113.10 (C3) 
165.15 47.61 14.96 96.41 
10a 
173.64 (C4); 160.02 (C7); 149.72 (C2); 147.51 
(C8a); 139.60 (C5); 124.14 (C4a); 116.57 (C6); 
113.11 (C3) 
165.16 47.52 14.93 96.39 
 
In 13C-NMR spectra analysis (table 2.4), the signal of the carbonyl carbon (C4) appears at 171-178 ppm 
and the aromatic carbons at: 159-162 ppm (C7), 148-155 ppm (C2), 147-149 ppm (C8a), 136-147 ppm 
(C5), 121-139 ppm (C4a), 116-121 ppm (C6) and 110-113 ppm (C3). The signal of carbon C9 appears at 
165 ppm. The carbon linked to the nitrogen atom (C1’) has a chemical shift of 46-48 ppm and the other 
carbon of this ethyl group (C2’) has a chemical shift of 14-15 ppm. On the alkoxyl chain, the carbon with 
lower chemical shift is the last one of the chain that is 13-14 ppm. On the other hand, the carbon with 
higher chemical shift in the alkoxyl chain (C1’’’) is the one linked to the oxygen of the ester group that 
has 60-71 ppm. Compounds 10 and 10a display a signal at 71 ppm for carbon C1’’’ since this carbon 
becomes tertiary in these compounds due to the methyl substitution instead of being secondary carbon 
like in the other esters with linear alkoxyl chains, and this fact leads to a higher chemical shift.  
These results show that between the two libraries of compounds there are no significant differences 
between the chemical shifts of aromatic carbons and carbons of the ethyl group linked to the nitrogen. 
The main difference in 13C-NMR spectra of the two libraries is the signal of carbon C1’’. On library 1, 
this carbon has a chemical shift 25 ppm and on library 2 of 96 ppm. This happens because on library 
one this carbon is linked to a methyl group but on library 2 is linked to a trichloromethyl group. Since 
the electronegativity of the chloro atom is higher than that of the hydrogen atom, the C1’’ signal on 
library 2 appears at a much higher chemical shift. 
 
 
2.3.2 Mass Spectrometry 
 
To confirm the structure of compounds of library 2, mass spectromety analysis of compound 9a was 
performed (Figure 2.10) 
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Figure 2. 10 - Mass spectrometry result of compound 9a. 
 
As it is possible to observe, the base peak is the peak with a m/z of 533.2, so it is the most intense ion 
with an abundance of 100%. Since the molecular weight of the compound 9a is 531.9, this peak 
represents the gain of a proton83.  
The most important result of this analysis is the confirmation of chlorine presence of the structure. 
Chlorine is composed by two isotopes 35Cl and 37Cl83. 
Since there are 3 chlorine atoms on the molecule, there are 8 possibles was to combine the isotopes. The 
only way these molecules can be distinguished is by their m/z values and there are 4 possible values: 
531.3, 533.2, 535.2 and 537.3. So with these results, it is possible to confirm the substitution of the 
methyl group in carbon C7 by a trichloromethyl group in compounds of library 2.  
  
Sample 144/16  MS Scan ESI+
m/z
175 200 225 250 275 300 325 350 375 400 425 450 475 500 525 550 575 600 625 650 675 700 725 750 775 800 825 850
%
0
100
LCMS_Service_20Abr2016_05 52 (0.524) Cm (45:63) 1: Scan ES+ 
1.44e8533.2
531.3
337.0
319.0 459.4339.0
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536.5
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655.6
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3. Stability and Activity Assays 
 
Chemical stability of the synthesized esters was studied in phosphate buffer pH=7.4 and human plasma. 
These assays are very important to evaluate the stability of all the synthesized compounds to hydrolysis 
(chemical and enzymatic) before they reach the mycobacteria. Hydrolysis of the esters was analysed 
through high performance liquid chromatography (HPLC) and it was observed the evolution with the 
time of ester (substrate) and acid (hydrolysis product) concentration. These studies have been performed 
as it’s described in chapter 7. 
The activity assays in vitro were performed by Nuno Carmo PhD from Host-Pathogen Interactions group 
of iMed ULisboa, led by Professor Elsa Anes. 
 
3.1 Stability Assays in Phosphate Buffer 
 
Chemical hydrolysis of esters was studied in phosphate buffer pH = 7.4 in order to evaluate the 
interference of this hydrolysis on the enzymatic assays. Phosphate buffer solution was prepared with a 
total concentration of 0.05 M, ionic strength 0.15 M and pH = 7.4. Chemical stability of all esters was 
evaluated in this pH in solutions with 2% of acetonitrile and at temperature of 37ºC - the pH and 
temperature of human body. Ester hydrolysis result on the appearance of the respective acid.  
In these assays, phosphate buffer pH 7.4 had a total concentration of 0.05M, ionic strength of 0.15, 2% 
of acetonitrile (ACN) and the initial concentration of substrates was 5x10-5M. To all the assays 
performed, pseudo-first order constants (kobs) and half-time lives (t1/2) were obtained as an estimation 
since the observed ester degradation was quite low and the necessary 3 t1/2 to obtain a good decay profile 
were never achieved. To compare these results with human plasma assays, it was also predicted the 
degradation in 72h of assay (time of human plasma assays). Those estimated results are shown on the 
table below (table 3.1).    
Table 3. 1 – Hydrolysis of compounds of libraries 1 and 2 in phosphate buffer pH=7.4.  
(Ct= 0.05M, I=0.15M with 2% of ACN) pH=7.4, T=37ºC, n=2 – number of samples for each compound. Initial concentration 
of substrate= 5x10-5M. 
Compound 
Library 1 
(10-3x)kobs/h-1 t1/2/day Degradation 
Degradation 
(% in 72h) 
2 0.31 92.7 8% in 356h 1.6 
3 0.35 82.4 9% in 356h 1.8 
4 0.42 67.4 11% in 356h 2.2 
5 1.1 26.3 14% in 177h 5.7 
6 1.7 16.8 22% in 177h 8.9 
7 0.8 33.7 11% in 178h 4.4 
8 2.1 13.8 31% in 157h 14.2 
9 3.6 8.0 52% in 207h 18.1 
10 0.9 33.3 13% in 208h 4.5 
Compound 
Library 2 
(10-3x)kobs/h-1 t1/2/day Degradation 
Degradation 
(% in 72h) 
3a 2.0 14.1 53% in 359h 10.6 
5a 3.6 7.8 44% in 165h 19.2 
6a 0.8 36.1 21% in 288h 5.3 
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Compound 
Library 2 
(10-3x)kobs/h-1 t1/2/day Degradation 
Degradation 
(% in 72h) 
7a 0.7 37.3 9% in 161h 4.0 
8a 1.1 26.4 13% in 165h 5.7 
9a 1.7 16.9 22% in 167h 9.5 
10a 0.8 38.2 9% in 165h 3.9 
 
In these assays it is possible to observe that kobs vary between 3.6x10-3 h-1 (compound 9 and 5a) and 
0.31x10-3 h-1 (compound 2). With these results it is possible to conclude that compound 2 is the most 
stable to chemical hydrolysis at pH 7.4 and at the temperature of 37ºC. It is also possible to conclude 
that compounds of library 1 are, in general, more stable than compounds of library 2. These studies also 
show that all the esters are very stable to chemical hydrolysis because all have long estimated half-time 
lives. The most unstable compound, 5a, has a t1/2 of 7.8 days which is a high t1/2. 
With these stability studies in phosphate buffer at pH 7.4 and T=37ºC, it is possible to observe that the 
disappearance of the ester corresponds to the acid formation (figures 3.1 and 3.2). These results were 
obtained in duplicate assays and the concentrations were calculated based on the calibration curves of 
each compound.  
 
Figure 3. 1 – Variation of ester and acid concentration during phosphate buffer (pH=7.4, T=37ºC) assay of ester 4. 
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Figure 3. 2 - Variation of ester and acid concentration during phosphate buffer (pH=7.4, T=37ºC) assay of ester 5a. 
 
On figure 3.1, it is possible to observe that compound 4 is very stable on phosphate buffer pH 7.4 at the 
temperature 37ºC since there is almost no degradation of the ester and then no formation of the 
correspondent acid. These results show that ester 4 is very stable to chemical hydrolysis, in those 
conditions of pH and temperature. 
With ester 5a in phosphate buffer – pH 7.4 and temperature 37ºC (figure 3.2) it is possible to observe 
the degradation of compound 5a and the formation of the correspondent acid. This compound is also 
very stable to chemical hydrolysis because his t1/2 is high (7.8 days) but is less stable than compound 4 
in the same conditions of pH and temperature. 
 
 
3.2 Stability Assays in Human Plasma  
 
To evaluate enzymatic hydrolysis, stability assays in human plasma were performed. The desirable 
result is that esters have low rates of hydrolysis in order to reach M. tuberculosis with good concentration 
and to be hydrolysed there by mycobacterial esterases.  
In these assays, 80% of human plasma was diluted in phosphate buffer pH 7.4 with total concentration 
of 0.05M, ionic strength of 0.15M, 2% of ACN and the initial concentration of substrates was 5x10-4M. 
Like with the phosphate buffer assays, in human plasma assays (kobs) and t1/2 were obtained as an 
estimation since the observed ester degradation was quite low and the 3 half-time lives could never be 
achieved within the established 72h the plasma stays active. Therefore, those estimates were evaluated 
to all the assays and are presented on the table 3.2.  
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Table 3. 2 - Hydrolysis of compounds of libraries 1 and 2 in 80% of human plasma suspension in phosphate buffer 
pH=7.4.  
(Ct= 0.05M, I=0.15M with 2% of ACN) pH=7.4, T=37ºC, n=3 – number of samples for each compound. Initial concentration 
of substrate= 5x10-4M. 
Compound 
Library 1 
(10-3x)kobs/h-1 t1/2/day Degradation (% in 72h) 
2 1.2 25 6 
3 nd nd nd 
4 nd nd nd 
5 1.2 25 6 
6 nd nd nd 
7 2.9 10 15 
8 nd nd nd 
9 nd nd nd 
10 nd nd nd 
Compound 
Library 2 
(10-3x)kobs/h-1) t1/2/day Degradation (% in 72h) 
3a 3.1 9.4 16 
5a 10.2 2.8 53 
6a 1.2 24.2 6.2 
7a nd nd nd 
8a 8.3 3.5 13 
9a nd nd nd 
10a nd nd nd 
nd – no visible degradation within the 72h of the plasma assays. 
The estimated results for the stability in human plasma show that all the compounds are very stable. The 
kobs vary between 10.2x10-3 h-1 (compound 5a) and 0.2x10-3 h-1 (compound 7) for the esters that have 
shown degradation. Like in phosphate buffer assays, compound 5a was the most susceptible for 
hydrolysis. For most of the esters it was not possible to calculate the kobs and the t1/2 because in 72h assay 
these esters did not hydrolyse at all. So, these results show that all the synthesized compounds are stable 
in human plasma.  
In these stability studies in 80% human plasma in phosphate buffer at pH 7.4, it is possible to observe 
that the disappearance of the ester corresponds to the acid formation, for those esters that suffered 
hydrolysis (figures 3.3 and 3.4). These results were obtained in triplicate assays and the concentrations 
along the assays were calculated with calibration curves of each compound.  
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Figure 3. 3 - Variation of ester and acid concentration during human plasma assay of ester 2. 
 
Figure 3. 4 - Variation of ester and acid concentration during human plasma assay of ester 5a. 
 
On figure 3.3, it is possible to observe that compound 2 is very stable in human plasma assays since 
there is almost no degradation of the ester and so no formation of the correspondent acid. These results 
show that ester 2 is very stable to human plasma enzymatic hydrolysis.  
On the other hand, it is possible to observe the degradation of compound 5a and the formation of the 
correspondent acid (figure 3.4). It is possible to conclude that this compound is also very stable to 
human plasma enzymatic hydrolysis because his t1/2 is high (2.8 days) even being less stable than 
compound 2.  
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3.3 Ratio between Human Plasma Stability/Phosphate Buffer pH 7.4 Stability 
 
To evaluate the contribution of chemical hydrolysis in human plasma enzymatic hydrolysis, pseudo-
first order constants obtained in phosphate buffer pH 7.4 assays were compared with those obtained in 
human plasma assays (enzymatic hydrolysis) – table 3.3. 
Table 3. 3 – Ration between (103x)kobs/(h-1) of plasma hydrolysis and (103x)kobs/(h-1) of phosphate buffer pH 7.4 
hydrolysis. 
Compound 
Library 1 
(103x)kobs/h-1 
Human plasma 
(103x)kobs/h-1 
Phosphate buffer 
Ratio 
(kplasma/kbuffer) 
2 1.2 0.31 4 
3 nd 0.35 - 
4 nd 0.42 - 
5 1.2 1.1 1.1 
6 nd 1.7 - 
7 2.9 0.8 3.6 
8 nd 2.1 - 
9 nd 3.6 - 
10 nd 0.9 - 
Compound 
Library 2 
(103x)kobs/h-1 
Human plasma 
(103x)kobs/h-1 
Phosphate buffer 
Ratio 
3a 3.1 2.0 1.6 
5a 10.2 3.6 2.8 
6a 1.2 0.8 1.5 
7a nd 0.7 - 
8a 8.3 1.1 7.5 
9a nd 1.7 - 
10a nd 0.8 - 
nd – no visible degradation within the 72h of the plasma assays. 
For some of the esters it was not possible to calculate the ratio between enzymatic hydrolysis (human 
plasma assays) and chemical hydrolysis (phosphate buffer pH 7.4 assays) because in plasma assays these 
compounds have a small degradation during the 72h – the time of the plasma assays. For compounds 2, 
5, 7, 3a, 5a, 6a and 8a it was possible to calculate the ratio because they have a little degradation within 
the 72h of human plasma assays. With these results it is possible to conclude that on esters 2, 7, 5a and 
8a kobs in human plasma enzymatic hydrolysis is higher than kobs of chemical hydrolysis, since the ratio 
values are 4, 3.6, 2.8 and 7.5, respectively. On the other esters (5, 3a and 6a), the results indicate that 
both kobs of human plasma enzymatic hydrolysis and chemical hydrolysis are very similar. It is possible 
to conclude this because the ratios obtained for these compounds are approximately 1.   
For compounds that was not possible to calculate the ratios (3, 4, 6, 8, 9, 10, 7a, 9a and 10a) are very 
stable to human plasma enzymatic hydrolysis because they have shown no degradation during the 72h 
of assay and so it was not possible to estimate a kobs and a t1/2.  
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3.4 Activity Studies in vitro 
 
Ester activities were studied in M. tuberculosis H37Rv strain, a virulent strain derived from the parent 
strain H37, that was primarily isolated from a patient with chronic pulmonary TB84. The results obtained 
are shown in the table below (Table 3.4) and the activities are presented in minimum inhibitory 
concentration (MIC90) in µM, which represents at least 90% of inhibition of the bacterial growth.  
Samples stock solutions were prepared in ethanol with a concentration of 10-2M and dilutions 1:100 
were performed to 96-well microplates (clear flat bottom) at a final volume of 200µL per well. The final 
concentrations in the 96-well microplates were in the range 100µM to 3.125 µM. All the compounds 
were tested against the recombinant M. tuberculosis H37Rv (pMV306hsp + LuxG13) provided by MTA 
Addgene. The medium used was 7H9 supplemented with OADC (oleic acid, albumin, dextrose and 
catalase). The assays were done for 5 days, at neutral pH, T=37ºC in a BSL3 incubator with 5% of CO2. 
The wavelength used to measure the optical densities was 600nm85–87. The MIC90 was defined as the 
lowest concentration of the compound effecting a reduction of 90% in absorbance relative to the 
controls, and the 50% inhibition the minimum concentration where a reduction in absorbance above 
50% was observed.  
 
Table 3. 4 – Results of activity assays in M. tuberculosis H37Rv performed by PhD Nuno Carmo from Host-Pathogen 
Interactions group of iMed ULisboa, lead by Professor Elsa Anes. 
Compound R 
MIC90 (% of 
inhibition)/µM 
%Inhibiton 
(100µM) 
1 H >100 9 
2 C2H5 >100 23 
3 C4H9 >100 8 
4 C6H13 >100 59 
5 C9H19 >100 79 
6 C10H21 >100 80 
7 C11H23 >100 76 
8 C12H25 100 100 
9 C14H29 >100 60 
10 C9H19 >100  82 
Compound R 
MIC90 (% of 
inhibition)/µM 
%Inhibiton 
(100µM) 
1a H >100 89 
3a C4H9 >100  84 
5a C9H19 100 93 
6a C10H21 50 94 
7a C11H23 100 90 
8a C12H25 100 92 
9a C14H29 >100 0 
10a C9H19 100 99 
 
The results obtained show that most of the MICs obtained do not have an exact value. In library 1, only 
compound 8 inhibit more than 90% in the bacterial growth. Although, in library 2, compounds 5a, 6a, 
7a, 8a and 10a inhibit more than 90% of the bacterial growth.  
The percentage of inhibition (table 3.4) was also calculated because MIC values give the minimum 
concentration to inhibit at least 90% of bacterial growth. Since some concentrations are higher than 
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100µM, it was interesting to understand if these compounds had some inhibition or if there was no 
activity at all. Through these values, it is possible to observe that compound 9a does not inhibit the 
bacterial growth, within the used concentration range, so is inactive against the virulent strain H37Rv of 
M. tuberculosis until the concentration of 100µM.  Compounds 2 and 3 are active but are not strong 
inhibitors because the bacterial growth was just inhibited by 23% and 8%, respectively. All the other 
compounds inhibit more than 50% of the bacterial growth. Compounds 6, 3a, 5a, 6a, 7a, 8a and 10a 
inhibit more than 80% so they have good activities against M. tuberculosis H37Rv strain. 
The MICs obtained showed that most of the compounds do not inhibit 90% of the bacterial growth with 
concentration of 100µM, so an estimation of 50% of inhibition was done, in order to observe which is 
the concentration that inhibits more than 50% of the bacterial growth. Compounds 1, 2, 3 and 9a, with 
the maximum concentration used, show a low percentage of inhibition (below 50%) so it was not 
possible to estimate the concentration that inhibits more than 50% of the bacterial growth. The results 
of this estimation are shown in figures 3.5 and 3.6.  
 
Figure 3. 5 - Estimation of 50% of inhibition of M. tuberculosis H37Rv strain growth by compounds of library 1. 
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Figure 3. 6 - Estimation of 50% of inhibition of M. tuberculosis H37Rv strain growth by compounds of library 1. 
The results of 50% of inhition estimation for compounds of library 1 (figure 3.5) show that the best 
compounds are 7 and 8, in this library. These compounds are needed in a concentration of 50µM to 
inhibit at least 50% of the bacterial growth. The other compounds are needed in a concentration of 
100µM, so they are less actives.  
In figure 3.6, there are presented the results of at least 50% of inhibition of bacterial growth for 
compounds of library 2. With these results, it is possible to conclude that compounds 6a is the most 
active because it inhibits at least 50% of bacterial growth with a concentration of 25µM. The other 
compounds are needed in a concentration of 50µM, except compound 1a that is needed in 100µM. 
These activity results in vitro show that compounds of library 2 have more activity against M. 
tuberculosis H37Rv strain than compounds of library 1, because the MICs obtained are lower (and it was 
possible to measure most of them) and for those whose inhibitory concentration stays above the 
concentration range of the assays the inhibition percentages observed at the concentration maximum 
used are higher, even above 80% of inhibition.  
Comparing both of the acids, compounds 1 and 1a, it is possible to observe that the MICs obtained do 
not have an exact value so an estimation of >50% of inhibition was done. It is possible to conclude that 
acid 1a is more active against M. tuberculosis H37Rv strain than acid 1. The inhibition resultant of the 
action of these acids in the bacteria are different because compound 1 only inhibits 9% of the bacterial 
growth and compound 1a inhibits 89%, which reveals that this compound is much higher active than 
acid 1. These results are concordant with the ones obtained for the esters (compounds of library 2 have 
more activity than compounds of library 1). 
So it is possible to conclude that the substitution of the methyl group to a trichloromethyl group on 
carbon C7 leads to more active compounds against M. tuberculosis H37Rv strain.   
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Discussion 
 
4.1 Synthesis and Structure Analysis  
 
In the present work, 16 different esters were synthetized and all of them are derivatives from NAL. To 
perform these synthesis, two different methods were used: Method A and Method B. Method A consists 
in the formation of the acyl chloride during 15 minutes and immediately the alcohol was added to obtain 
the desired ester; this last reaction is kept under reflux during 1h. In method B, first the acyl chloride 
was synthesized (in a 2h reaction kept under reflux) and after the alkoxyde of the correspondent alcohol 
was added to the acyl chloride to synthesize the ester. This last reaction was kept under reflux and 
controlled by thin layer chromatography (TLC) until the product (the ester) was formed. 
The main difference between the esters of each library is the group in carbon C7: in library 1 the methyl 
stays intact but it library 2 it was substituted by a trichloromethyl group (Figure 4.1). For library 1, 9 
different esters were synthesized with different alkoxyl chains, from 2 until 14 carbons length. The 
yields were obtained within a range from 51% until 79%. For library 2, 6 different esters were 
synthesized with different alkoxyl chains, from 4 until 14 carbons length. The yields were obtained with 
a range from 5% to 35%. 
  
 
Characterization of all the compounds was done through NMR analysis. To identify the structures, 1H, 
13C, APT, HMQC and HMBC were made to see all the signals and correlations. In figure 4.2, it is 
presented the general structure of compounds from both libraries with the main carbons numbered. 
 
 
 
 
 
 
 
After 1H spectra analysis of the esters, it is possible to observe that the chemical shifts of the aromatic 
protons are different between the two libraries but they appeared in the same order: C5-H > C2-H > C6-
Figure 4. 1 - Starting material of the obtained compounds. In compound 1, R1 is a CH3 group. In compound 1a, R1 is a 
CCl3 group. 
Library 1 Library 2 
Figure 4. 2 - General structure of compounds from libraries 1 and 2 with the main carbons numbered. 
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H. Library 2 aromatic protons have a higher chemical shifts due to the substitution of a methyl group to 
a trichloromethyl in aromatic carbon C7. This happens because chloro’s electronegativity is much higher 
than hydrogen’s, which means that a trichloromethyl group has a higher electronegativity than a methyl 
group88. The chemical shift of a NMR signal depends on the local magnetic environment of the nucleous 
and this is influenced by the electron density53. So, it was expected that the substitution of the methyl 
group for the trichloro group led to higher chemical shifts of the protons signal.  
Acids (compounds 1 and 1a) 1-H spectra revealed different results in the chemical shifts of aromatic 
protons. In these compounds, the chemical shifts appeared as: C2-H > C5-H > C6-H. These results 
showed that there is an exchange of position of C5-H and C2-H, when comparing with the esters spectra; 
that fact be due to the carboxylic acids be more polar than the esters so it will lead to a higher chemical 
shift for C2-H, which is the aromatic proton near these organic functions.  
The main difference between the 1H spectra of the two libraries is the existence of a singlet at 2.58-2.66 
ppm in library 1 that do not exist in library 2. This singlet corresponds to the methyl group attached to 
carbon C7. In library 2, the hydrogens are substituted by three chloro atoms so that peak does not exist 
on 1H spectra of all the compounds in this library. 
All the compounds synthesized have similar spectra on the alkoxyl chain except compounds 10 and 10a 
because these compounds have a methyl group attached do carbon C1’’’ (first carbon of the alkoxyl 
chain). So, in these compounds, this carbon is chiral, that means an asymmetric atom which implies that 
the two protons of the next carbon (C2’’’) are non-equivalent called diastereotopic. So, two different 
signals appeare d in the 1H-NMR spectra. Therefore, instead of C2’’’-H signal be a multiplet, in 
compounds 10 and 10a there are two multiplets for these protons, one for each hidrogen.  
Coupling constants give us the information of which protons are coupled because these values are the 
same for signals from coupling protons53. So, coupling constants were calculated for duplets, triplets 
and quadriplets. With the values obtained, it is possible to conclude that the coupled protons are: 
 C5’-H and C6’-H, with JC5-H-C6-H ≈ 8.1 – 8.4 Hz; 
 C1’-H and C2’-H, with JC1’-H-C2’-H = 8.2 Hz. 
The other coupling constants obtained were not mentioned above because the protons couple with more 
than one group of protons leading to a multiplet signal and it is not possible to calculate constants for 
these kinds of signals.  
In 13C-NMR spectra results, the attribution of the signals to the right carbon was made with the help of 
APT spectra and also HMQC and HMBC correlations. APT spectra gives positive or negative peaks as 
a way to encode information about the number and type of protons attached to a carbon (Cq, CH, CH2 
or CH3)89. These spectra were very useful to distinguish signals with similar chemical shifts: C2 has a 
chemical shift of 149.78 ppm and C8a has a chemical shift of 147.48 ppm so it only possible to made the 
right atribution with APT spectra. HMQC spectra correlates the protons in a molecule with the carbon 
atoms to which they are directly attached90. HMBC spectra correlates protons with nearby carbon atoms, 
not the carbon to which the proton is directly attached90. All these spectra (1H, 13C, APT, HMQC and 
HMBC) allowed understanding better the real structure of the compounds and to make the right 
attribution of all the carbons signals.    
After the analysis of all the spectra, it was possible to observe that aromatic and C9 carbons have a 
chemical shift between 110 and 178 ppm, that are the normal resonances for aromatic carbons and 
carbons of carboxylic acids attached to aromatic rings91. Besides that, it was also possible to observe 
that chemical shifts of C1’ and C2’ do not show relevant differences between both libraries of compounds 
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(46-48 ppm and 14-15 ppm, respectively). On the alkoxyl chain, the last carbon has a chemical shift of 
13-14 ppm for all the esters, since the chemical shifts of CH3 of alkane chains go down to low fields91. 
On the other hand, the carbon of the alkoxyl chain with higher chemical shift is the first, C1’’’, since is 
the one linked to the esters’ oxygen. This carbon has a chemical shift between 60-71 ppm. In compounds 
10 and 10a, chemical shift of C1’’’ has the value of 71 ppm because this carbon becomes tertiary due to 
the methyl substitution instead of secondary as with the other esters.  
Analysis of 13C spectra only reveals one big difference between compounds of both libraries. In library 
1, carbon C1’’ has a chemical shift of 24-25 ppm but in library 2 of 96 ppm. This difference happens 
because in library 1 this carbon is linked to three hydrogens and in library 2 is linked to three chloro 
atoms. Chloro atoms are more electronegative than hydrogen atoms so the chemical shift of the carbon 
which they are attached to increases53,88,91.  
Mass spectrometry analysis confirms the presence of the trichloromethyl group on carbon C7 of 
compounds of library 2.  
  
4.2 Stability Assays 
 
Plasma and buffer stability assays were performed in order to evaluate enzymatic and chemical 
hydrolysis, respectively.  
Primarily, all the compounds were diluted in ACN at different concentrations to do calibration curves 
in order to obtain the relation to convert the HPLC area values into concentrations on the other assays. 
After this, the esters were tested in human plasma and phosphate buffer suspensions. Samples were 
taken at different times and injected in the HPLC to observe the ester hydrolysis and the acid formation 
(Figure 4.3).  
 
 
 
 
 
 
To calculate kobs and t1/2, a pseudo-first order kinetics was assumed because the kinetic decay observed 
was similar to a first order kinetics.  
Human plasma assays were performed with 80% of human plasma suspension in phosphate buffer. 
These assays were done to evaluate compound’s enzymatic stability. The results obtained show that all 
the esters are very stable in human plasma because some of them did not show any visible degradation 
(compounds 3, 4, 6, 8, 9, 10, 7a, 9a and 10a) within the 72h of the assays and the rest of them have t1/2 
in the order of days. The less stable ester was 5a with a t1/2 of 2.8 days, which is yet a high t1/2. When 
comparing the two libraries of compounds, it is possible to observe that compounds of library 1 are more 
stable, in general, than compounds in library 2. Since the only difference between them is the group in 
carbon C7, it is possible to conclude that this difference is due to the introduction of a trichloromethyl 
group instead of a methyl group.  
Figure 4. 3 – Ester hydrolysis in human plasma and phosphate buffer assays.   
  
40 
 
In phosphate buffer assays, the aim was to evaluate chemical hydrolysis, as it was mentioned above. 
The assays were performed with samples removed at different times. These results show that all the 
synthesized esters are very stable to chemical hydrolysis because all the t1/2 obtained were in the order 
of days and the kobs vary between 0.31 and 3.6 x103 h-1. The most stable compound in these assays is 
compound 2, with a kobs of 0.31x103 h-1 and a t1/2 of 92.7 days. On the other hand, the less stable 
compounds are 9 and 5a with a kobs of 3.6x103 h-1 and a t1/2 of 7.8 days. Even among the compounds 
under study the less stable, these compounds are still very stable because their t1/2 is quite high.  
To evaluate the contribution of chemical hydrolysis in human plasma enzymatic hydrolysis, kobs of the 
both assays were compared, calculating the ratio between kplasma/kbuffer. This is very important because 
human plasma assays were performed in human plasma with phosphate buffer so it is necessary to 
estimate which is the contribution of phosphate buffer hydrolysis. For some esters it was not possible to 
calculate the ratios, since they are very stable in human plasma assays, they did not show visible 
degradation within the assays time so it was not possible to calculate kplasma for them (compounds 3, 4, 
6, 8, 9, 10, 7a, 9a and 10a). Calculation of the ratios of compounds 2, 5, 7, 3a, 5a, 6a and 8a (table 8, 
chapter 3.3) show that all of them have a value above 1. Compounds 2, 7, 5a and 8a have a higher 
enzymatic hydrolysis than chemical hydrolysis because obtained ratios vary between 2.8 and 7.5. For 
compounds 5, 3a, 5a and 6a, the ratios obtained are approximately 1, so it is possible to conclude that 
human plasma enzymatic hydrolysis is very similar to phosphate buffer chemical hydrolysis.  
With these stability results it is possible to conclude that all the compounds under study are very stable. 
These results are very good since it is expected to these compounds to act on macrophages infected with 
M. tuberculosis, they must survive to plasma transportation in order to reach the target site77.  
 
4.3 Activity Assays 
 
All the compounds have good results in stability assays so they were tested in order to evaluate their 
activity against M. tuberculosis H37Rv strain.  
H37 was originally isolated in 1905 and earned attention for its noted virulence in the guinea pig model. 
In 1934, H37 was dissociated into “virulent” (Rv) and “avirulent” (Ra) strains92. H37Rv strain was used 
to evaluate the activity of the synthesized esters. To evaluate the activity of the compounds, it was 
measured the MIC90 in µM, which represents the minimum concentration the inhibits at least 90% of 
the bacterial growth. The results of activity studies are presented in table 3.4.  
All the esters and the acids have activity against M. tuberculosis H37Rv, except compound 9a. The most 
active compound is compound 6a, an ester with 10 carbons on the alkoxyl chain and a trichloromethyl 
substitute on carbon C7.  This compound has a MIC90 of 50µM. 
Since most of the compounds do not show an exact concentration of MIC90, it was analysed the 
inhibition of at least 50% of the bacterial growth. Compounds 1, 2, 3 and 9a still do not have an exact 
value on this estimation, which means that they only inhibit less than 50% of the bacterial growth. The 
other compounds have activity at this inhibition percentage. The concentration needed to achieve this 
value of growth are low and the best result corresponds again to compound 6a, that is only needed 25µM 
of it to inhibit at least 50% of the bacterial growth.  
To evaluate better the activity studies results, the percentage of inhibition was also calculated for a 
concentration of 100µM (table 4.1).  
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Table 4. 1 – Percentage of inhibition of the bacterial growth M. tuberculosis H37Rv strain to a concentration of 100µM. 
Compound %Inhibition 
1 9 
2 23 
3 8 
4 59 
5 79 
6 80 
7 76 
8 100 
9 60 
10 82 
Compound %Inhibition 
1a 89 
3a 84 
5a 93 
6a 94 
7a 90 
8a 92 
9a 0 
10a 99 
 
With these percentages values, it is possible to observe that the compound with higher inhibition of the 
bacterial growth with a concentration of 100µM is compound 8. This compound promotes an inhibition 
of 100%. The less active compounds in a concentration of 100µM are 1, 2 and 3 with an inhibition of 9, 
23 and 8%, respectively. Compound 9a does not inhibit bacterial growth at the considered concentration. 
So, these four compounds are considered the worse in terms of inhibition of the growth of M. 
tuberculosis H37Rv strain. Both libraries of compounds have good inhibition results but library 2 has 
higher inhibition percentages (between 84-99%, except compound 9a) than library 1 (between 59-100%, 
except compounds 1, 2 and 3). 
With these activity assays results, it is possible to conclude that compounds of library 2 are, in general, 
more active than compounds of library 1. The only difference between the two libraries of compounds 
is the trichloromethyl group instead of a methyl group. So, the difference of activities between the two 
libraries of compounds must be due to this substitution in carbon C7. 
All the synthesized compounds are NAL derivatives, so it is expected that they have the same target. 
NAL is a quinolone and the target of this kind of compounds in bacteria is DNA gyrase, a type II 
topoisomerase93.  It is thought that the toxicity of quinolones in bacterial cell is due to the formation of 
a topoisomerase-drug-DNA ternary complex that cellular processes convert into a lethal lesion94. In fact, 
it is suggested that quinolones bind to multiple points along the helix-4 of DNA gyrase with carbon C7 
near position 81 (Figure 4.).In this position, the aminoacid is a glycine95. This aminoacid has a nonpolar 
side chain, that is an hydrogen56. It is also suggested that carboxyl and keto oxygens of quinolones are 
near GyrA, near Asp87 and Ser83 residues, respectively (Figure 4.4)95. 
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Figure 4. 4 - Model of quinolone binding to GyrA-GyrA dimer of DNA gyrase. Substitute on carbon C7 is near Gly81. 
Carboxyl and keto oxygens are near Asp87 and Ser83, respectively95. 
 
Although, there are several suggested mechanisms of DNA gyrase inhibition by quinolones so more 
studies are necessary to understand how these compounds are actives against M. tuberculosis.    
The synthesized compounds in this study are derivatives of NAL. These compounds are esters so they 
are more lipophilic than NAL, which means that they may cross biological membranes easily96. It is 
expected that, after they cross the cell membrane of M. tuberculosis, they will be degradated by 
mycobacterial esterases. The product of this enzymatic hydrolysis is NAL, compound 1 or the 
synthesized derivative of it, compound 1a for compounds of libraries 1 and 2, respectively.  
As it was mentioned before, they difference between compounds 1 and 1a is the presence of a methyl 
group or a trichloromethyl group in carbon C7, respectively. It is possible to observe that compounds of 
library 2 are more active than compounds of library 1 so this difference may be due to the 
trichloromethyl substitution. 
 
 
4.4 Structure-activity relationship 
 
There are some parameters that are very important in drug design. One of them is lipophilicity. Cell 
membranes are composed principally of phospholipid bilayers, that are formed with polar ionised head 
groups and a highly hydrophobic inner core. To cross this bilayer membrane, molecules must be 
hydrophobic97. So, lipophilicity represents the affinity of a molecule for a lipophilic environment. This 
characteristic is expressed by the partition coefficient (logP) that is defined as the ratio of concentrations 
of the compound at equilibrium between the organic and aqueous phases97,98. Esters are lipophilic 
molecules so they are good options as prodrugs to enhance the entrance of drugs inside the cell54. 
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In this chapter, to sum all the data, it is established the relation between structural characteristics of all 
the synthesized compounds with their plasma stability and activity against M. tuberculosis. In table 4.2 
it is presented all the structural characteristics and also stability and activity results for each compound.  
Table 4. 2 – Structural characteristics, plasma stability and activity against H37Rv strain of M. tuberculosis results for 
each compound. The logP values were calculated with AlogPs software and pKa values with ACD/I-Lab. nd – no 
degradation.  
 
 
 
 
Compound R logP pKa1 pKa2 kplasma %degradation %inhibition  
1 H 0.95 4.5 6.2 - - 9 
2 C2H5 2.27 
4.6 - 
1.2 6 23 
3 C4H9 3.13 nd nd 8 
4 C6H13 3.95 nd nd 59 
5 C9H19 5.28 1.2 6 79 
6 C10H21 5.77 nd nd 80 
7 C11H23 6.34 2.9 15 76 
8 C12H25 6.50 nd nd 100 
9 C14H29 6.84 nd nd 60 
10 CH(CH3)C7H15 5.34 nd nd 82 
Compound R logP pKa1 pKa2 kplasma %degradation %inhibition  
1a H 2.78 4.5 6.1 - - 89 
3a C4H9 4.5 
4.6 - 
3.1 16 84 
5a C9H19 6.39 10.2 53 93 
6a C10H21 6.75 1.2 6.2 94 
7a C11H23 7.07 nd nd 90 
8a C12H25 7.30 8.3 13 92 
9a C14H29 7.80 nd nd 0 
10a CH(CH3)C7H15 6.35 nd nd 99 
 
Through table 4.2, it is possible to observe that the acids have two pKa values (pKa1 and pKa2) but the 
synthesized esters only have one (pKa1). It was expected that the substitution on carbon C7 lead to a 
higher pKa1 value but no differences were observed on the estimations. This pKa value is 4.6 which 
means that at pH 4.6 that half of the molecules are protonated in this position. These estimated pKa 
values indicate that compounds 1 and 1a are weak acids. In fact, it was previously demonstrated that M. 
tuberculosis is susceptible to weak acids and to acid pH. The differential disruption of membrane in M. 
tuberculosis caused by weak acids could result from the slow metabolism and, consequently, slow 
energy production in the slow growing of the bacteria and a defective efflux mechanism78. 
The alkoxyl chain length of the derivatives may have influence in the activity of the compound against 
M. tuberculosis H37Rv strain and in the stability in plasma.  
Relationship between kobs values and number of carbons of alkoxyl chain (figure 4.5), between 
inhibition percentage and number of carbons of alkoxyl chain (figures 4.6 and 4.7) and between 
inhibition percentage and lipophilicity (figures 4.8 and 4.9) are established bellow. 
pKa1 
pKa2 
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Figure 4. 5 – Relationship between alkoxyl chain length and kobs value (plasma).  
 
In figure 4.5, it is possible to observe that there is not a correlation between the length of alkoxyl chain 
and plasma stability. In library 1, there is no possible conclusion but in library 2, in general, it is possible 
to assume that, except for compound 6a, when the alkoxyl chain is longer, plasma stability decreases. 
These results indicate that higher alkoxyl chains are not beneficial to stability. 
 
 
Figure 4. 6 - Relationship between alkoxyl chain length and inhibition percentage of M. tuberculosis H37Rv growth for 
a concentration of 100µM of compounds of library 1. 
The relationship between the inhibition percentage and number of carbons of the alkoxyl chain for 
compounds of library 1 is shown above (figure 4.6). In this library, it is possible to observe that when 
number of carbons of the alkoxyl chain is higher, the inhibition percentage is also higher, except for 
compound 9. This result indicates that for this library of compounds higher alkoxyl chains lead to an 
increase on the activity of the compounds.  
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Figure 4. 7 - Relationship between alkoxyl chain length and inhibition percentage of M. tuberculosis H37Rv growth for 
a concentration of 100µM of compounds of library 2. 
 
For compounds of library 2 (figure 4.7) it is possible to conclude that the length of the alkoxyl chain 
have no direct influence on the activity results, except for compound 9a. Since this compound has the 
biggest alkoxyl chain maybe it has no activity because it is very liposoluble. As it is possible to observe 
on the graphic above, the inhibition percentage of compounds from library 2 is similar between all of 
them so it is possible to conclude that the activity of these compounds is not mainly due to the length of 
the alkoxyl chain but to the fact that these compounds have a trichloromethyl group on carbon C7. Since 
there is no relationship between inhibition percentage and alkoxyl chain length maybe there are some 
other factors that are important for transportation through membranes for these compounds, such as, 
membrane transporters. 
Hydrophilic/Hydrophobic properties of a drug are crucial in influencing its solubility and ADMET96. 
Molecules that are very polar or too hydrophilic do not cross the cell membranes, that are constituted by 
phospholipids96,97.  However, very hydrophobic drugs are likely to be dissolved in fat globules and are 
poorly absorbed, when they are administrated orally. On the other hand, if they are injected, they are 
poorly soluble in blood and are likely to be taken up by fat tissue, so the circulating levels of the drug 
are low96. So, it is necessary to find an equilibrium between hydrophilia and lipophilia of the drug.  
As it was mentioned before, the property used to evaluate this characteristic of the drug is logP. 
Hydrophobic compounds have high logP values and hydrophilic have low values. In general, the 
susceptibility of M. tuberculosis to weak acids increases with the logP value of the compound, that is 
due to the fact that lipophilic prodrugs enter into the mycobacteria easily99.    
In table 4.2 is possible to conclude that, as it is expected, the logP value increases with the size of the 
alkoxyl chain. This is due to the fact that esters with larger alkoxyl chains are more lipophilic so logP 
values increase. High values of logP are good because the synthesized compounds have to be lipophilic 
to cross the bacteria membrane that is constituted by mycolic acids that measure the sensitivity to 
hydrophobic antibiotics13,54.  
It is expected that compounds with higher logP values are more active against M. tuberculosis H37Rv 
strain and, also, to have a higher stability in human plasma.  
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Figure 4. 8 - Relationship between alkoxyl logP and percentage of inhibition of M. tuberculosis H37Rv strain growth 
for a concentration of 100µM for compounds of library 1. 
 
In figure 4.8, it is possible to observe that, in general, when the logP value is higher, the inhibition 
percentage is also higher. The exceptions to this conclusion are compounds 3 (alkoxyl chain with 4 
carbons length), 7 (alkoxyl chain with 11 carbons length) and 9 (alkoxyl chain with 14 carbons length).  
 
Figure 4. 9 - Relationship between logP and percentage of inhibition of M. tuberculosis H37Rv strain growth for a 
concentration of 100µM for compounds of library 2. 
 
In figure 4.9, it is shown the relation between inhibition growth of M. tuberculosis H37Rv strain and 
lipophilia for compounds of library 2. By this figure, it is possible to observe that logP values do not 
have influence in the percentage inhibition, except for compound 9a. As it is possible to observe, the 
inhibition percentage is almost the same for all the compounds, even for compounds with higher logP. 
These results, combined with the results of figure 4.5 (for compounds of library 2) show that the activity 
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of these compounds may not be due to the lipophilia but to the existence of a trichloromethyl group in 
carbon C7.  
Compounds of library 2 are more lipophilic than compounds of library 1. In fact, compound 1a is an 
acid and inhibits 89% of the bacterial growth. This compound has a logP value of 2.78 so it has a 
favourable logP to cross M. tuberculosis cell wall, which explains the difference of activity between this 
compound and NAL (compound 1) that has a logP value of 0.95. 
This conclusion arises because compounds of library 1 show differences in activity with the variation 
of logP and this does not happen with compounds of library 2. As it was mentioned before, the only 
difference between the two libraries is the substitution of a methyl group (in library 1) to a 
trichloromethyl group (in library 2) in carbon C7. So, activity of compounds of library 2 can only be 
explained by the existence of this group.   
In figure 4.10 it is shown the relationship between plasma stability and lipophilicity.  
 
Figure 4. 10 – Relationship between lipophilicity and plasma stability. 
 
Like the relationship between plasma stability and number of carbons of the alkoxyl chain, there is no 
relationship between plasma stability and lipophilicity for compounds of library 1. For compounds of 
library 2, it is possible to observe that more lipophilic compounds are less stable in plasma, except for 
compound 6a. Although, there was not possible to obtain more kobs because most of the compounds did 
not show degradation in human plasma assays within the 72h of assay. So, since there are only a few 
values of kobs, there was not possible to conclude something in particular about the relationship between 
plasma stability and lipophilicity/number of carbons of the alkoxyl chain.  
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4. Conclusion 
 
In the synthesis of NAL derivatives two methods were performed: method A and method B. Method A 
consists in the addiction of NAL to thionyl chloride and addiction of the alcohol 15 minutes later. In 
method B, NAL reacts with thionyl chloride for 2h and the alkoxide ion, previously synthesized, is 
added. Method A was used to synthesize compounds of library 1, compounds with an alkoxyl chain 
between 2 and 14 carbons length. The yields obtained were in a range between 51% (compound 5) and 
79% (compound 10). Compounds of library 2 have an alkoxyl chain between 4 and 14 carbons length 
and were synthesized with method B. The yields obtained for this library were in a range between 5% 
(compounds 5a and 6a) and 35% (compound 9a). So it is possible to conclude that, with method A, the 
yields of compounds are much better than the yields of compounds synthesized with method B.  
One of the most important aims of prodrugs is their stability in human plasma because it is necessary 
that they achieve the pretended target without being degradated by human enzymes. In this work, all the 
compounds are very stable in human plasma being the less stable compound is 5a with a t1/2 of 2.8 days 
and 53% of degradation in 72h. Compounds 3, 4, 6, 8, 9, 10, 7a, 9a and 10a are the most stable because 
they did not show any degradation within the 72h of assay. 
Comparison of pseudo-first order constants obtained in human plasma and phosphate buffer assays give 
the contribution of chemical hydrolysis in enzimatic hydrolysis. It is possible to conclude that, for 
compounds 2, 7, 5a and 8a, the contribution of chemical hydrolysis is low because the ratios obtained 
were above 2. For compounds 5, 3a and 6a, the ratios obtained were similar to 1 so it is possible to 
conclude that chemical hydrolysis has the same contribution on as the enzymatic hydrolysis.  
It is important that compounds have a good plasma stability but they have to be active against M. 
tuberculosis. Studies in M. tuberculosis H37Rv strain showed that all the compounds, except compound 
9a, are active against the bacteria. This means that the compounds can enter the bacterial cell envelope 
and might be activated (transformation of the ester in the correspondent carboxylic acid) inside it.  
Compounds 8, 5a, 6a, 7a, 8a and 10a were the ones with best results in activity assays. All of them have 
a MIC90 of 100µM, except compound 5a that has a MIC90 of 50µM. So, compound 5a is the most active. 
When analyzing the percentages of inhibition of bacterial growth at a concentration of 100µM, it is 
possible to observe that the percentages of inhibition are quite high. In fact, the compounds that show 
lower inhibition on the bacterial growth are compounds 1 (9%), 2 (23%), 3 (8%) and 9a (0%). All the 
other compounds inhibit more than 59% of the bacterial growth. One interesting result is that compound 
1a, that is not an ester, but inhibits 89%.  With these results, it is possible to conclude that compounds 
of library 2 are more active against H37Rv M. tuberculosis strain than compounds of library 1.  
The most promising compound is 6a. This compound had a t1/2 of 24.2 days in human plasma assays, so 
it is very stable to enzymatic hydrolysis and it was thr most active compound tested against M. 
tuberculosis H37Rv strain.  
To conclude, the main objective of the present work was achieved because NAL derivatives were 
synthesized and the compounds are quite resistant to plasmatic proteins hydrolysis and are active against 
M. tuberculosis. 
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5. Future perspectives 
 
In the future, more studies with these compounds are necessary. Firstly, studies in liver homogenate are 
necessary in order to confirm stability of compounds with hepatic enzymes. Studies in mycobacteria 
homogenate are also necessary to confirm that mycobacterial esterases are capable of activate the 
compounds. The activity assays in vitro against M. tuberculosis H37Rv strain showed that most of the 
compounds can inhibit bacterial growth, which means that they might be activated but it is necessary to 
confirm this fact. Besides that, it is necessary to evaluate which compounds are easily activated by 
mycobacterial esterases.  
Another type of studies that has to be performed is toxicity studies. It is necessary to evaluate if the 
synthesized compounds are toxic for humans, to understand if these compounds are suitable to 
administration or not. There are also necessary modelation studies to understand how the compounds, 
by themselves or the correspondent acid, interact with the DNA gyrase and/or with DNA molecules by 
some type of complex. Some studies refer that quinolones are sterilizing agents which means that they 
kill the bacteria definitely100. So, activity studies should include sterilazation analysis.       
In the end, in vivo studies must be executed. 
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6. Experimental Procedure 
 
7.1 Equipment and material 
 
NMR spectra were done on Magnet System 300 MHz/54 mm Ultrashield, long hold time Bruker. The 
chemical shifts are expressed in ppm (parts per million) and the coupling constants (J) in Hertz (Hz). 
The spectra obtained are presented in the followed form: Nucleus (solvent): chemical shift (δ, 
ppm)[multiplicity (s- singlet, d- doublet, t- triplet, q- quartet, m- multiplet], coupling constant (J, Hz), 
relative intensity (nH, for number of protons), molecule attribution]. To characterize the compounds, 1H 
and 13C spectra were performed. 
The melting points were measured on Bock-Monoscop <M> apparatus.  
The HPLC studies were performed on VWR chromatograph constituted with two pumps VWR-Hitachi 
L-2160U, one UV detector VWR-Hitachi L-2400U, one column oven VWR-Hitachi L-2300 and one 
autosampler VWR-Hitachi L-2200U. The column used was LiChroCART R250-4 HPLC Cartridge 
LiChrospherR 100 reversed phase RP-8 (5 µm) MERCK. The analysis of the chromatograms was done 
with Agilent EZ Chrom Elite software.  
To perform Thin Layer Chromatography (TLC), used to follow reactions and column chromatography, 
aluminium sheets with silica gel 60 F254 (Merck) were used.  The revelation of the chromatograms was 
performed with UV light 366 nm and a camera that contains a mixture of silica and iodide.  
Columns of glass (different sizes) filled with silica gel 60 (0.063-0.200 nm) were used in order to isolate 
and purify the compounds.  
 
7.2 Reagents and Solvents 
 
The solvents used were acquired from: José Manuel Gomes dos Santos Lda and António M. S. Cruz 
Lda.  
The reagents used were acquired from: Sigma-Aldrich® and Fluka®. 
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7.3 Synthesis  
 
Ethyl 1-ethyl-1,4-dihydro-7-methyl-1,8-naphthyridine-4-oxo-3-carboxylate (2) 
 
To synthesize this derivative, 82.70 mmol (6.00 mL) of thionyl 
chloride was added to 4.35 mmol (1.01 g) of NAL and the flask 
was kept aside for 15 minutes. Later 0.12 mol (6.80 mL) of 
ethanol was added to the solution, drop by drop and mixed 
thoroughly after each addition, and the reaction was kept for 
refluxing during 1h.  
Then, the excess of thionyl chloride was evaporated and the 
organic phase was obtained after washing with 2x10 mL of 
sodium chlorine, 3x10mL of sodium bicarbonate and 3x5mL of ethyl acetate and drying with sodium 
sulfate anhydrous. Then, the solvent was evaporated and the organic phase was purified by column 
chromatography (9/1 to 1/1, hexane/ethyl acetate). 
White solid, η= 65% 
1H-NMR δ (300 MHz, CDCl3): 8.65 (d, J=8.1 Hz, 1H, C5-H); 8.63 (s, 1H, C2-H); 7.24 (d, J=8.1 Hz, 
1H, C6-H); 4.49 (q, J=7.2 Hz, 2H, C1’-H); 4.41 (t, J=7.2 Hz, 2H, C1’’’-H); 2.66 (s, 3H, C1’’-H); 1.50 (t, 
J=7.2 Hz, 3H, C2’-H); 1.42 (t, J=7.2 Hz, 3H, C2’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 174.74 (C4); 165.64 (C9); 162.66 (C7); 148.74 (C2); 148.58 (C8a); 
136.86 (C5); 121.51 (C4a); 121.14 (C6); 112.48 (C3); 60.81 (C1’’’); 46.53 (C1’); 24.96 (C1’’); 15.03 (C2’); 
14.36 (C2’’’)  
Melting point:  128-130ºC 
 
Butyl 1-ethyl-1,4-dihydro-7-methyl-1,8-naphthyridine-4-oxo-3-carboxylate (3) 
 
To synthesize this derivative, 82.70 mmol (6.00 mL) of 
thionyl chloride was added to 4.35 mmol (1.01 g) of NAL 
and the flask was kept aside for 15 minutes. Later 0.15 
mol (10.98 g) of 1-butanol was added to the solution, drop 
by drop and mixed thoroughly after each addition, and the 
reaction was kept for refluxing during 1h.  
Then, the excess of thionyl chloride was evaporated and 
the organic phase was obtained after washing with 2x10 
mL of sodium chlorine, 3x10mL of sodium bicarbonate and 4x5mL of ethyl acetate and drying with 
sodium sulfate anhydrous. Then, the solvent was evaporated and the organic phase was purified by 
column chromatography (7/3 to 1/1, hexane/ethyl acetate). 
White solid, η= 68% 
1H-NMR δ (300 MHz, CDCl3): 8.63 (d, J= 8.1 Hz, 1H, C5-H); 8.60 (s, 1H, C2-H); 7.23 (d, J= 8.1 Hz, 
1H, C6-H); 4.48 (q, J= 7.2 Hz, 2H, C1’-H); 4.33 (t, J= 6.6 Hz, 2H, C1’’’-H); 2.65 (s, 3H, C1’’-H); 1.77 
(m, 2H, C2’’’-H); 1.48 (m, 5H, C3’’’-H and C2’-H); 0.96 (t, J= 7.8 Hz, C4’’’-H) 
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13C-NMR δ (75.48 MHz, CDCl3): 174.71 (C4); 165.77 (C9); 162.62 (C7); 148.68 (C2); 148.60 (C8a); 
136.86 (C5); 121.52 (C4a); 121.10 (C6); 112.06 (C3); 64.84 (C1’’’); 46.57 (C1’); 30.83 (C2’’’); 25.08 (C1’’); 
19.29 (C3’’’); 15.22 (C2’); 13.83 (C4’’’) 
Melting point: 94-96ºC 
 
Hexyl 1-ethyl-1,4-dihydro-7-methyl-1,8-naphthyridine-4-oxo-3-carboxylate (4) 
 
To synthesize this derivative, 82.70 mmol (6.00 
mL) of thionyl chloride was added to 4.31 mmol 
(1.00 g) of NAL and the flask was kept aside for 15 
minutes. Later 0.15 mol (15.16 g) of 1-hexanol was 
added to the solution, drop by drop and mixed 
thoroughly after each addition, and the reaction was 
kept for refluxing during 1h.  
Then, the excess of thionyl chloride was evaporated 
and the organic phase was obtained after washing with 10 mL of sodium chlorine, 2x10mL of sodium 
bicarbonate and 3x5mL of ethyl acetate and drying with sodium sulfate anhydrous. Then, the solvent 
was evaporated and the organic phase was purified by column chromatography (7/3 to 1/1, hexane/ethyl 
acetate). 
White solid, η= 59% 
1H-NMR δ (300 MHz, CDCl3): 8.57 (d, J= 8.1 Hz, 1H, C5-H); 8.54 (s, 1H, C2-H); 7.16 (d, J= 8.1 Hz, 
1H, C6-H); 4.41 (q, J= 7.2 Hz, 2H, C1’-H); 4.26 (t, J= 6.9 Hz, 2H, C1’’’-H); 2.59 (s, 3H, C1’’-H); 1.72 
(m, 2H, C2’’’-H); 1.42 (t, J= 7.2 Hz, 3H, C2’-H); 1.30-1.23 (m, 6H, C3’’’-H, C4’’’-H and C5’’’-H); 0.82 (t, 
J= 6.9 Hz, 3H, C6’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 174.74 (C4); 165.72 (C9); 162.63 (C7); 148.66 (C2); 148.62 (C8a); 
136.89 (C5); 121.53 (C4a); 121.11 (C6); 112.06 (C3); 65.16 (C1’’’); 46.57 (C1’); 31.52 (C2’’’); 28.73 (C3’’’); 
25.68 (C4’’’); 25.08 (C1’’); 22.55 (C5’’’); 15.21 (C2’); 14.06 (C6’’’) 
Melting point: 70-73ºC 
 
Nonyl 1-ethyl-1,4-dihydro-7-methyl-1,8-naphthyridine-4-oxo-3-carboxylate (5) 
 
To synthesize this derivative, 16.54 mmol (1.20 mL) 
of thionyl chloride was added to 0.86 mmol (0.20 g) 
of NAL and the flask was kept aside for 15 minutes. 
Later 29.67 mmol (4.28 g) of 1-nonanol was added 
to the solution, drop by drop and mixed thoroughly 
after each addition, and the reaction was kept for 
refluxing during 1h.  
Then, the excess of thionyl chloride was evaporated and the organic phase was obtained after washing 
with 2x10 mL of sodium chlorine, 3x10mL of sodium bicarbonate and 2x5mL of ethyl acetate and 
drying with sodium sulfate anhydrous. Then, the solvent was evaporated and the organic phase was 
purified by column chromatography (7/3 to 1/1, hexane/ethyl acetate). 
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White solid, η= 51% 
1H-NMR δ (300 MHz, CDCl3): 8.57 (d, J= 8.1 Hz, 1H, C5-H); 8.53 (s, 1H, C2-H); 7.16 (d, J= 8.1 Hz, 
1H, C6-H); 4.41 (q, J= 7.2 Hz, 2H, C1’-H); 4.25 (t, J= 6.9 Hz, 2H, C1’’’-H); 2.58 (s, 3H, C1’’-H); 1.72 
(m, 2H, C2’’’-H); 1.42 (t, J= 7.2 Hz, 3H, C2’-H); 1.30-1.13 (m, 12H, C3’’’-H-C8’’’-H); 0.80 (t, J= 7.2 Hz, 
3H, C9’’’-H)  
13C-NMR δ (75.48 MHz, CDCl3): 174.73 (C4); 165.72 (C9); 162.62 (C7); 148.66 (C2); 148.61 (C8a); 
136.89 (C5); 121.54 (C4a); 121.10 (C6); 112.07 (C3); 65.17 (C1’’’); 46.57 (C1’); 31.87 (C2’’’); 29.49 (C3’’’); 
29.35 (C4’’’); 29.29 (C5’’’); 28.77 (C6’’’); 26.00 (C7’’’); 25.08 (C1’’); 22.67 (C8’’’); 15.21 (C2’); 14.12 (C9’’’);  
Melting point: 76-79ºC   
 
Decyl 1-ethyl-1,4-dihydro-7-methyl-1,8-naphthyridine-4-oxo-3-carboxylate (6) 
 
To synthesize this derivative, 16.54 mmol (1.20 
mL) of thionyl chloride was added to 0.86 mmol 
(0.20 g) of NAL and the flask was kept aside for 
15 minutes. Later 29.69 mmol (4.70 g) of 1-
decanol was added to the solution, drop by drop 
and mixed thoroughly after each addition, and 
the reaction was kept for refluxing during 1h. 
Then, the excess of thionyl chloride was evaporated and the organic phase was obtained after washing 
with 2x10 mL of sodium chlorine, 3x10mL of sodium bicarbonate and 5mL of dichloromethane and 
drying with sodium sulfate anhydrous. Then, the solvent was evaporated and the organic phase was 
purified by column chromatography (7/3 to 1/1, hexane/ethyl acetate). 
White solid, η= 60% 
 1H-NMR δ (300 MHz, CDCl3): 8.65 (d, J= 8.1 Hz, 1H, C5-H); 8.61 (s, 1H, C2-H); 7.24 (d, J= 8.1 Hz, 
1H, C6-H); 4.48 (q, J= 7.2 Hz, 2H, C1’-H); 4.33 (t, J= 6.9 Hz, 2H, C1’’’-H); 2.66 (s, 3H, C1’’-H); 1.79 
(m, 2H, C2’’’-H); 1.49 (t, J= 7.2 Hz, 3H, C2’-H); 1.36-1.24 (m, 14H, C3’’’-H-C9’’’-H); 0.87 (t, J= 6.9 Hz, 
3H, C10’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 174.72 (C4); 165.73 (C9); 162.62 (C7); 148.66 (C2); 148.62 (C8a); 
136.89 (C5); 121.54 (C4a); 121.10 (C6); 112.07 (C3); 65.17 (C1’’’); 46.57 (C1’); 31.89 (C2’’’); 29.58 (C3’’’); 
29.53 (C4’’’); 29.34 (C5’’’); 29.32 (C6’’’); 28.77 (C7’’’); 25.99 (C8’’’); 25.08 (C1’’); 22.68 (C9’’’); 15.21 (C2’); 
14.12 (C10’’’) 
Melting point: 85-89ºC 
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Undecyl 1-ethyl-1,4-dihydro-7-methyl-1,8-naphthyridine-4-oxo-3-carboxylate (7) 
 
To synthesize this derivative, 16.54 mmol 
(1.20 mL) of thionyl chloride was added to 
0.86 mmol (0.20 g) of NAL and the flask was 
kept aside for 15 minutes. Later 29.71 mmol 
(5.12 g) of 1-undecanol was added to the 
solution, drop by drop and mixed thoroughly 
after each addition, and the reaction was kept 
for refluxing during 1h. 
Then, the excess of thionyl chloride was evaporated and the organic phase was obtained after washing 
with 2x10 mL of sodium chlorine, 3x10mL of sodium bicarbonate and 3x5mL of dichloromethane and 
drying with sodium sulfate anhydrous. Then, the solvent was evaporated and the organic phase was 
purified by column chromatography (7/3 to 1/1, hexane/ethyl acetate). 
White solid, η= 65% 
1H-NMR δ (300 MHz, CDCl3): 8.65 (d, J= 8.1 Hz, 1H, C5-H); 8.61 (s, 1H, C2-H); 7.24 (d, J= 8.1 Hz, 
1H, C6-H); 4.48 (q, J= 7.2 Hz, 2H, C1’-H); 4.33 (t, J= 6.9 Hz, 2H, C1’’-H); 2.66 (s, 3H, C1’’-H); 1.79 (m, 
2H, C2’’’-H); 1.49 (t, J= 7.2 Hz, 3H, C2’-H); 1.37-1.26 (m, 16H, C3’’’-H-C10’’’-H); 0.88 (t, J= 7.2 Hz, 3H, 
C11’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 174.71 (C4); 165.74 (C9); 162.61 (C7); 148.66 (C2); 148.62 (C8a); 
136.89 (C5); 121.55 (C4a); 121.09 (C6); 112.09 (C3); 65.18 (C1’’’); 46.56 (C1’); 31.91 (C2’’’); 29.63 (C3’’’ 
and C4’’’); 29.53 (C5’’’); 29.35 (C6’’’ and C7’’’); 28.77 (C8’’’); 26.00 (C9’’’); 25.08 (C1’’); 22.69 (C10’’’); 15.22 
(C2’); 14.13 (C11’’’)  
Melting point: 72-74ºC 
 
Dodecyl 1-ethyl-1,4-dihydro-7-methyl-1,8-naphthyridine-4-oxo-3-carboxylate (8) 
 
To synthesize this derivative, 16.54 mmol 
(1.20 mL) of thionyl chloride was added to 
0.86 mmol (0.20 g) of NAL and the flask was 
kept aside for 15 minutes. Later 29.62 mmol 
(5.52 g) of 1-dodecanol was added to the 
solution, drop by drop and mixed thoroughly 
after each addition, and the reaction was kept 
for refluxing during 1h. 
Then, the excess of thionyl chloride was evaporated and the organic phase was obtained after washing 
with 2x10 mL of sodium chlorine, 3x10mL of sodium bicarbonate and 5mL of dichloromethane and 
drying with sodium sulfate anhydrous. Then, the solvent was evaporated and the organic phase was 
purified by column chromatography (7/3 to 1/1, hexane/ethyl acetate). 
 
Yellow solid, η= 66% 
1H-NMR δ (300 MHz, CDCl3): 8.65 (d, J= 8.1 Hz, 1H, C5-H); 8.61 (s, 1H, C2-H); 7.24 (d, J= 8.1 Hz, 
1H, C6-H); 4.48 (q, J= 7.2 Hz, 2H, C1’-H); 4.33 (t, J= 6.9 Hz, 2H, C1’’’-H); 2.66 (s, 3H, C1’’-H); 1.79 
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(m, 2H, C2’’’-H); 1.49 (t, J= 7.2 Hz, 3H, C2’-H); 1.37-1.26 (m, 18H, C3’’’-H-C11’’’-H); 0.88 (t, J= 6.9 Hz, 
3H, C12’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 174.73 (C4); 165.72 (C9); 162.63 (C7); 148.66 (C2); 148.61 (C8a); 
136.89 (C5); 121.54 (C4a); 121.11 (C6); 112.07 (C3); 65.18 (C1’’’); 46.57 (C1’); 31.92 (C2’’’); 29.67 (C3’’’); 
29.64 (C4’’’ and C5’’’); 29.53 (C6’’’); 29.35 (C7’’’ and C8’’’); 28.78 (C9’’’); 26.00 (C10’’’); 25.08 (C1’’); 22.69 
(C11’’’); 15.22 (C2’); 14.13 (C12’’’) 
Melting point: 61-64ºC 
 
Tetradecyl 1-ethyl-1,4-dihydro-7-methyl-1,8-naphthyridine-4-oxo-3-carboxylate carboxylate (9) 
 
To synthesize this derivative, 16.54 mmol 
(1.20 mL) of thionyl chloride was added to 
0.86 mmol (0.20 g) of NAL and the flask was 
kept aside for 15 minutes. Later 29.67 mmol 
(6.36 g) of 1-tetradecanol was added to the 
solution, drop by drop and mixed thoroughly 
after each addition, and the reaction was kept 
for refluxing during 1h. 
Then, the excess of thionyl chloride was evaporated and the organic phase was obtained after washing 
with 2x10 mL of sodium chlorine, 3x10mL of sodium bicarbonate and 2x5mL of dichloromethane and 
drying with sodium sulfate anhydrous. Then, the solvent was evaporated and the organic phase was 
purified by column chromatography (7/3 to 1/1, hexane/ethyl acetate). 
 
Yellow solid, η= 63%                                                                                                                                                                                                
1H-NMR δ (300 MHz, CDCl3): 8.57 (d, J= 8.1 Hz, 1H, C5-H); 8.54 (s, 1H, C2-H); 7.17 (d, J= 8.1 Hz, 
1H, C6-H); 4.41 (q, J= 7.2 Hz, 2H, C1’-H); 4.25 (t, J= 6.9, 2H, C1’’’-H); 2.59 (s, 3H, C1’’-H); 1.72 (m, 
2H, C2’’’-H); 1.42 (t, J= 7.2 Hz, 3H, C2’-H); 1.24-1.18 (m, 22H, C3’’’-H-C13’’’-H); 0.80 (t, J= 6.9 Hz, 3H, 
C14’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 174.74 (C4); 165.72 (C9); 162.63 (C7); 148.66 (C2); 148.61 (C8a); 
136.89 (C5); 121.53 (C4a); 121.11 (C6); 112.07 (C3); 65.18 (C1’’’); 46.57 (C1’); 31.92 (C2’’’); 29.69 (C3’’’ 
and C4’’’); 29.67 (C5’’’ and C6’’’); 29.63 (C7’’’); 29.53 (C8’’’); 29.36 (C9’’’ and C10’’’); 28.77 (C11’’’); 26.00 
(C12’’’); 25.08 (C1’’); 22.69 (C13’’’); 15.21 (C2’); 14.14 (C14’’’) 
Melting point: 69-71ºC 
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1-Methyloctyl 1-ethyl-1,4-dihydro-7-methyl-1,8-naphthyridine-4-oxo-3-carboxylate (10) 
 
To synthesize this derivative, 16.54 mmol 
(1.20 mL) of thionyl chloride was added to 
0.86 mmol (0.20 g) of NAL and the flask was 
kept aside for 15 minutes. Later 29.60 mmol 
(4.27 g) of 2-nonanol was added to the 
solution, drop by drop and mixed thoroughly 
after each addition, and the reaction was kept 
for refluxing during 1h. 
Then, the excess of thionyl chloride was evaporated and the organic phase was obtained after washing 
with 2x10 mL of sodium chlorine, 3x10mL of sodium bicarbonate and 2x5mL of dichloromethane and 
drying with sodium sulfate anhydrous. Then, the solvent was evaporated and the organic phase was 
purified by column chromatography (7/3 to 1/1, hexane/ethyl acetate). 
Yellow solid, η= 79% 
1H-NMR δ (300 MHz, CDCl3): 8.64 (d, J= 8.1 Hz, 1H, C5-H); 8.57 (s, 1H, C2-H); 7.23 (d, J= 8.1 Hz, 
1H, C6-H); 5.17 (m, 1H, C1’’’-H); 4.48 (q, J= 7.2 Hz, 2H, C1’-H); 2.65 (s, 3H, C1’’-H); 1.83-1.73 (m, 1H, 
C2’’’-H); 1.67-1.56 (m, 1H, C2’’’-H); 1.49 (t, J= 7.2 Hz, 3H, C2’-H); 1.36 (d, J= 6.3 Hz, 3H, CH3-C1’’’-
H); 1.35-1.22 (m, 10H, C3’’’-H-C7’’’-H); 0.87 (t, J= 6.9 Hz, 3H, C8’’’-H) 
 13C-NMR δ (75.48 MHz, CDCl3): 174.76 (C4); 165.07 (C9); 162.54 (C7); 148.62 (C2); 148.37 (C8a); 
136.87 (C5); 121.52 (C4a); 121.02 (C6); 112.49 (C3); 71.72 (C1’’’); 46.52 (C1’); 36.06 (CH3-C1’’’); 31.83 
(C2’’’); 29.47 (C3’’’); 29.21 (C4’’’); 25.54 (C5’’’); 25.06 (C1’’); 22.64 (C6’’’); 20.13 (C7’’’); 15.19 (C2’); 14.09 
(C8’’’) 
Melting point: 75-77ºC  
 
7-Trichloromethyl-1-ethyl-1,4-dihydro-1,8-naphtyridine-4-oxo-3-carboxylic acid (1a)  
 
To synthesize this NAL derivative, 41.35 mmol (3.00 mL) of 
thionyl chloride were added to 2.15 mmol (0.5 g) of NAL. The 
reaction was kept under reflux for two hours, in order to form the 
acyl chloride. After that, the excess of thionyl chloride was 
evaporated. 
To form the carboxylic acid, water was added to the acyl chloride 
and this reaction was kept under reflux overnight. 
Then, the organic phase was obtained after washing 2x5 mL of dichloromethane and drying with sodium 
sulfate anhydrous. Then, the solvent was evaporated.  
Brown solid, η= 100% 
1H-NMR δ (300 MHz, CDCl3): 14.21 (sbr, C9- OH); 9.03 (s, 1H, C2-H), 8.99 (d, J= 8.4 Hz, 1H, C5-H); 
8.22 (d, J= 8.4 Hz, 1H, C6-H); 4.67 (q, J= 7.2 Hz, 2H, C1’-H); 1.63 (t, J= 7.2 Hz, 3H, C2’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 178.04 (C4); 165.85 (C9); 161.52 (C7); 155.21 (C2); 149.73 (C8a); 
147.44 (C5); 139.16 (C4a); 121.89 (C6); 117.84 (C1’’); 110.82 (C3); 48.56 (C1’); 15.09 (C2’) 
Melting point: 180-183ºC  
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Butyl 7-Trichloromethyl-1-ethyl-1,4-dihydro-1,8-naphthyridine-4-oxo-3-carboxylate (3a) 
 
To synthetize this ester from the NAL derivative, 82.70 mmol 
(6.00 mL) of thionyl chloride were added to 4.31 mmol (1.00 g) 
of NAL. The reaction was kept in reflux for two hours, in order 
to form the acyl chloride. After that, the excess of thionyl chloride 
was evaporated.  
To form the alkoxide, 4.32 mmol (0.32 g) 1-butanol were added 
to 32.08 mmol (0.77 g) of sodium hydride. The alkoxide was 
mixed with the acyl chloride and the reaction was kept under 
reflux for 18 hours.  
Then, the organic phase was obtained after washing with 2x10 mL of sodium chlorine, 3x10mL of 
sodium bicarbonate and 2x5mL of ethyl acetate and drying with sodium sulfate anhydrous. Then, the 
solvent was evaporated and the organic phase was purified by column chromatography (9/1 to 1/1, 
hexane/ethyl acetate). 
 
White solid, η= 21% 
1H-NMR δ (300 MHz, CDCl3): 8.92 (d, J= 8.1 Hz, 1H, C5-H); 8.70 (s, 1H, C2-H); 8.06 (d, J= 8.1 Hz, 
1H, C6-H); 4.52 (q, J= 7.2 Hz, 2H, C1’-H); 4.36 (t, J= 6.6 Hz, 2H, C1’’’-H); 1.79 (m, 2H, C2’’’-H); 1.57 
(t, J= 7.2 Hz, 3H, C2’-H); 1.48 (m, 2H, C3’’’-H); 0.99 (t, J= 7.5 Hz, 3H, C4’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 173.69 (C4); 165.18 (C9); 160.02 (C7); 149.78 (C2); 147.48 (C8a); 
139.55 (C5); 124.08 (C4a); 116.59 (C6); 113.07 (C3); 96.39 (C1’’); 65.14 (C1’’’); 47.64 (C1’); 30.79 (C2’’’); 
19.28 (C3’’’); 14.98 (C2’); 13.83 (C4’’’) 
Melting point: 113-115ºC 
   
Nonyl 7-trichloromethyl-1-ethyl-1,4-dihydro-1,8-naphthyridine-4-oxo-3-carboxylate (5a) 
 
To synthesize this ester, 82.70 mmol (6.00 mL) of 
thionyl chloride were first added to 4.35 mmol (1.01 g) 
of NAL. The reaction was kept under reflux for two 
hours, in order to form the acyl chloride. After that, the 
excess of thionyl chloride was evaporated.  
To form the alkoxide, 4.30 mmol (0.62 g) 1-nonanol 
were added to 6.67 mmol (0.16 g) of sodium hydride. 
The alkoxide was mixed with the acyl chloride and the reaction was kept under reflux for 19 hours.  
Then, the organic phase was obtained after washing with 10 mL of sodium chlorine, 2x10mL of sodium 
bicarbonate and 5mL of dichloromethane and drying with sodium sulfate anhydrous. Then, the solvent 
was evaporated and the organic phase was purified by column chromatography (9/1 to 1/1, hexane/ethyl 
acetate). 
White solid, η= 5% 
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1H-NMR δ (300 MHz, CDCl3): 8.93 (d, J= 8.1 Hz, 1H, C5-H); 8.71 (s, 1H, C2-H); 8.06 (d, J= 8.1 Hz, 
1H, C6-H); 4.53 (q, J= 7.2 Hz, 2H, C1’-H); 4.36 (t, J= 6.9 Hz, 2H, C1’’’-H); 1.81 (m, 2H, C2’’’-H); 1.58 
(t, J= 7.2 Hz, 3H, C2’-H); 1.28 (m, 12H, C3’’’-H-C8’’’-H); 0.89 (t, J= 6.9 Hz, 3H, C9’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 171.71 (C4); 165.15 (C9); 160.03 (C7); 149.74 (C2); 147.48 (C8a); 
139.57 (C5); 124.09 (C4a); 116.58 (C6); 113.09 (C3); 96.40 (C1’’); 65.46 (C1’’’); 47.62 (C1’); 31.88 (C2’’’); 
29.49 (C3’’’); 29.33 (C4’’’); 29.28 (C5’’’); 28.73 (C6’’’); 25.98 (C7’’’); 22.68 (C8’’’); 14.96 (C2’); 14.12 (C9’’’) 
Melting point: 74-76ºC 
 
Decyl 7-trichloromethyl-1-ethyl-1,4-dihydro-1,8-naphthyridine-4-oxo-3-carboxylate (6a) 
 
To synthesize this derivative, 0.13 mol (10.00 mL) of thionyl 
chloride were added to 6.02 mmol (1.39 g) of NAL. The 
reaction was kept under reflux for two hours, in order to 
form the acyl chloride. After that, the excess of thionyl 
chloride was evaporated.  
To form the alkoxide, 4.98 mmol (0.95 mL) 1-decanol were 
added to 7.51 mmol (0.18 g) of sodium hydride. The alkoxide was mixed with the acyl chloride and the 
reaction was kept under reflux for 11 hours.  
Then, the organic phase was obtained after washing with 10 mL of sodium chlorine, 2x10 mL of sodium 
bicarbonate and 2x5 mL of dichloromethane and drying with sodium sulfate anhydrous. Then, the 
solvent was evaporated and the organic phase was purified by column chromatography (9/1 to 1/1, 
hexane/ethyl acetate). 
 
1H-NMR δ (300 MHz, CDCl3): 8.93 (d, J= 8.1 Hz, 1H, C5-H); 8.71 (s, 1H, C2-H); 8.07 (d, J= 8.1 Hz, 
1H, C6-H); 4.53 (q, J= 7.2 Hz, 2H, C1’-H); 4.36 (t, J= 6.9 Hz, 2H, C1’’’-H); 1.83 (m, 2H, C2’’’-H); 1.58 
(t, J= 7.2 Hz, 3H, C2’-H); 1.28 (m, 14H, C3’’’-H-C9’’’-H); 0.89 (t, J= 6.9 Hz, 3H, C10’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 173.74 (C4); 165.19 (C9); 160.01 (C7); 149.77 (C2); 147.52 (C8a); 
139.59 (C5); 124.10 (C4a); 116.57 (C6); 113.09 (C3); 96.44 (C1’’); 65.36 (C1’’’); 47.63 (C1’); 31.90 (C2’’’); 
29.63 (C3’’’); 29.61(C4’’’); 29.38 (C5’’’); 29.34 (C6’’’); 28.64 (C7’’’); 26.03(C8’’’); 22.69 (C9’’’); 14.97 (C2’); 
14.12 (C10’’’) 
Melting point: 69-73ºC 
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Undecyl 7-trichloromethyl-1-ethyl-1,4-dihydro-1,8-naphthyridine-4-oxo-3-carboxylate (7a) 
 
To synthesize this derivative, 82.70 mmol (6.00 mL) of 
thionyl chloride were added to 4.31 mmol (1.00 g) of 
NAL. The reaction was kept under reflux for two hours, 
in order to form the acyl chloride. After that, the excess 
of thionyl chloride was evaporated.  
To form the alkoxide, 4.35 mmol (0.75 g) 1-undecanol 
were added to 7.08 mmol (0.17 g) of sodium hydride. The alkoxide was mixed with the acyl chloride 
and the reaction was kept under reflux for 11 hours.  
Then, the organic phase was obtained after washing with 10 mL of sodium chlorine, 10mL of sodium 
bicarbonate and 2x5mL of dichloromethane and drying with sodium sulfate anhydrous. Then, the 
solvent was evaporated and the organic phase was purified by column chromatography (9/1 to 1/1, 
hexane/ethyl acetate). 
Yellow solid, η= 15% 
1H-NMR δ (300 MHz, CDCl3): 8.92 (d, J= 8.4 Hz, 1H, C5-H); 8.69 (s, 1H, C2-H); 8.06 (d, J= 8.4 Hz, 
1H, C6-H); 4.52 (q, J= 7.2 Hz, 2H, C1’-H); 4.35 (t, J= 6.9 Hz, 2H, C1’’’-H); 1.80 (m, 2H, C2’’’-H); 1.57 
(t, J= 7.2 Hz, 3H, C2’-H); 1.26 (m, 16H, C3’’’-H-C10’’’-H); 0.88 (t, J= 6.9 Hz, 3H, C11’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 173.72 (C4); 165.73 (C9); 160.03 (C7); 149.68 (C2); 147.49 (C8a); 
139.56 (C5); 124.09 (C4a); 116.55 (C6); 113.06 (C3); 96.42 (C1’’); 65.43 (C1’’’); 47.65 (C1’); 31.94 (C2’’’); 
29.64 (C3’’’ and C4’’’); 29.61 (C5’’’); 29.39 (C6’’’ and C7’’’); 28.98 (C8’’’); 26.02 (C9’’’); 22.66 (C10’’’); 14.96 
(C2’); 14.13 (C11’’’) 
Melting point: 77-80ºC  
 
Dodecyl 7-trichloromethyl-1-ethyl-1,4-dihydro-1,8-naphthyridine-4-oxo-3-carboxylate (8a) 
To synthesize this derivative, 0.13 mol (10.00 mL) of 
thionyl chloride were added to 6.03 mmol (1.40 g) of 
NAL. The reaction was kept under reflux for two 
hours, in order to form the acyl chloride. After that, the 
excess of thionyl chloride was evaporated.  
To form the alkoxide, 5.13 mmol (0.96 g) 1-dodecanol 
were added to 7.92 mmol (0.19 g) of sodium hydride. The alkoxide was mixed with the acyl chloride 
and the reaction was kept in reflux for 40 hours.  
Then, the organic phase was obtained after washing with 10 mL of sodium chlorine, 10mL of sodium 
bicarbonate and 2x5mL of dichloromethane and drying with sodium sulfate anhydrous. Then, the 
solvent was evaporated and the organic phase was purified by column chromatography (9/1 to 1/1, 
hexane/ethyl acetate). 
Yellow solid, η= 15% 
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 1H-NMR δ (300 MHz, CDCl3): 8.93 (d, J= 8.4 Hz, 1H, C5-H); 8.71 (s, 1H, C2-H); 8.07 (d, J= 8.4 Hz, 
1H, C6-H); 4.53 (q, J= 7.2 Hz, 2H, C1’-H); 4.36 (t, J= 6.9 Hz, 2H, C1’’’-H); 1.81 (m, 2H, C2’’’-H); 1.58 
(t, J= 7.2 Hz, 3H, C2’-H); 1.27 (m, 18H, C3’’’-H-C11’’’-H); 0.89 (t, J= 6.9 Hz, 3H, C12’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 173.86 (C4); 165.77 (C9); 159.99 (C7); 149.59 (C2); 147.65 (C8a); 
139.89 (C5); 124.11 (C4a); 116.58 (C6); 113.12 (C3); 96.35 (C1’’); 65.56 (C1’’’); 47.63 (C1’); 31.94 (C2’’’); 
29.68 (C3’’’); 29.65 (C4’’’ and C5’’’); 29.63 (C6’’’); 29.35 (C7’’’ and C8’’’); 28.87 (C9’’’); 26.02 (C10’’’); 22.71 
(C11’’’); 14.94 (C2’); 14.13 (C12’’’) 
Melting point: 72-74ºC 
 
Tetradecyl 7-trichloromethyl-1-ethyl-1,4-dihydro-1,8-naphthyridine-4-oxo-3-carboxylate (9a) 
To synthesize this derivative, 82.70 mmol (6.00 
mL) of thionyl chloride were added to 4.31 
mmol (1.00 g) of NAL. The reaction was kept 
under reflux for two hours, in order to form the 
acyl chloride. After that, the excess of thionyl 
chloride was evaporated.  
To form the alkoxide, 4.29 mmol (0.92 g) 1-
tetradecanol were added to 30.83 mmol (0.74 g) of sodium hydride. The alkoxide was mixed with the 
acyl chloride and the reaction was kept under reflux for 16 hours.  
Then, the organic phase was obtained after washing with 2x10 mL of sodium chlorine, 3x10mL of 
sodium bicarbonate and 2x5mL of ethyl acetate and drying with sodium sulfate anhydrous. Then, the 
solvent was evaporated and the organic phase was purified by column chromatography (9/1 to 1/1, 
hexane/ethyl acetate). 
Yellow solid, η= 35% 
1H-NMR δ (300 MHz, CDCl3): 8.84 (d, J= 8.1 Hz, 1H, C5-H); 8.62 (s, 1H, C2-H); 7.98 (d, J= 8.1 Hz, 
1H, C6-H); 4.44 (q, J= 7.2 Hz, 2H, C1’-H); 4.27 (t, J= 6.9 Hz, 2H, C1’’’-H); 1.73 (m, 2H, C2’’’-H); 1.49 
(t, J= 7.2 Hz, 3H, C2’-H); 1.18 (m, 22H, C3’’’-H-C13’’’-H); 0.81 (t, J= 6.9 Hz, 3H, C14’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 173.69 (C4); 165.15 (C9); 160.03 (C7); 149.75 (C2); 147.49 (C8a); 
139.57 (C5); 124.10 (C4a); 116.57 (C6); 113.10 (C3); 96.41 (C1’’); 65.46 (C1’’’); 47.61 (C1’); 31.93 (C2’’’); 
29.69 (C3’’’ and C4’’’); 29.67 (C5’’’ and C6’’’); 29.63 (C7’’’); 29.54 (C8’’’); 29.37 (C9’’’); 29.33 (C10’’’); 28.73 
(C11’’’); 25.98 (C12’’’); 22.70 (C13’’’); 14.96 (C2’); 14.14 (C14’’’) 
Melting point: 73-75ºC 
 
1-Methy,octyl 7-trichloromethyl-1-ethyl-1,4-dihydro-1,8-naphthyridine-4-oxo-3-carboxylate 
(10a) 
 
To synthesize this derivative, 82.70 mmol (6.00 mL) 
of thionyl chloride were added to 4.31 mmol (1.00 g) 
of NAL. The reaction was kept under reflux for two 
hours, in order to form the acyl chloride. After that, the 
excess of thionyl chloride was evaporated.  
To form the alkoxide, 4.34 mmol (0.62 g) 2-nonanol 
were added to 30.83 mmol (0.74 g) of sodium hydride. 
The alkoxide was mixed with the acyl chloride and the reaction was kept under reflux for 11 hours.  
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Then, the organic phase was obtained after washing with 2x10 mL of sodium chlorine, 3x10mL of 
sodium bicarbonate and 2x5mL of ethyl acetate and drying with sodium sulfate anhydrous. Then, the 
solvent was evaporated and the organic phase was purified by column chromatography (9/1 to 1/1, 
hexane/ethyl acetate). 
Yellow oil, η= 20% 
1H-NMR δ (300 MHz, CDCl3): 8.91 (d, J= 8.4 Hz, 1H, C5-H); 8.66 (s, 1H, C2-H); 8.05 (d, J= 8.4 Hz, 
1H, C6-H); 5.18 (m, 1H, C1’’’-H); 4.52 (q, J= 7.2 Hz, 2H, C1’-H); 1.79 (m, 1H, C2’’-H); 1.64 (m, 1H, C2’’-
H); 1.58 (t, J= 7.2 Hz, 3H, C2’-H); 1.37 (d, J= 6.3 Hz, 3H, CH3-C1’’’-H); 1.48-1.22 (m, 10H, C3’’’-H-
C7’’’-H); 0.87 (t, J= 6.9 Hz, 3H, C8’’’-H) 
13C-NMR δ (75.48 MHz, CDCl3): 173.64 (C4); 165.16 (C9); 160.02 (C7); 149.72 (C2); 147.51 (C8a); 
139.60 (C5); 124.14 (C4a); 116.57 (C6); 113.11 (C3); 96.39 (C1’’); 71.74 (C1’’’); 47.52 (C1’); 36.83 (CH3-
C1’’’); 31.84 (C2’’’); 29.58 (C3’’’); 29.34 (C4’’’); 25.97 (C5’’’); 22.88 (C6’’’); 20.21 (C7’’’); 14.93 (C2’); 14.09 
(C8’’’) 
 
 
7.4 Ester stability assays 
 
Kinetic studies were develop and analysed through HPLC to observe the decrease of ester concentration 
and the increase of acid at different times.  
Before starting the kinetic studies, the right eluent for each derivative was chosen to avoid that ester’s 
and acid’s retention times were similar in order to obtain a good separation in the chromatogram. Two 
different eluents were chosen. For the esters 2, 3, 4 and 3a the mobile phase contained 50% of acetonitrile 
and 50% of water. For the other esters, the mobile phase was constituted by 85% of acetonitrile and 15% 
of water. All the analysis were performed with 1 mL/min flow rate, 20 µL of injection volume and a 
wavelength of 265 nm.  
The values of kobs were calculated through linear regression: 
− 𝑘obs =  
ln(𝑐𝑜𝑛𝑐.)𝑡
ln(𝑐𝑜𝑛𝑐.)0
  
 
(conc)t is the determinated concentrations over the time and (conc)0 is the concentration at the beginning 
of the assays (t=0).   
 
7.4.1  Stability assays in phosphate buffer pH 7.4 
 
A phosphate buffer solution was prepared with a concentration of 0.05M and ion force of 0.15M (Anex 
I). The assays were performed with 5x10-5M of initial concentration of substrate. At different times, 
samples were removed and were analysed through HPLC.  
 
7.4.2 Stability assays in human plasma 
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The stability assays were performed in a solution of 80% of human plasma and 20% of phosphate buffer 
pH = 7.4, concentration of 0.05M and ion force of 0.15M at 37ºC. The incubation medium were field 
with acetonitrile (2%) and the substrate were added from stock solutions of 10-1 M em acetonitrile. The 
hydrolysis reactions were performed with 5x10-4M of initial concentration of substrate.  
At specific time, 50µL of the sample was added to 450µL of acetonitrile in order to stop the hydrolysis 
reaction. Then, the samples were centrifuged at 15000 rpm for 10 minutes and the supernatants were 
analysed through HPLC.     
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Anex I - Calculation for the preparation of a phosphate buffer solution pH 7.4, 
concentration 0.05M and ionic force of 0.15M  
To prepare the phosphate buffer solutions with pH 7.4, concentration 0.05M and ionic force of 
0.15M, it was done the following calculations based on the equations101.  
pH of the solution: 
 
𝑝𝐾𝑎′ = 𝑝𝐾𝑎 − (2𝑛 − 1) × 𝑐𝑜𝑟𝑟. <=> 𝑝𝐾𝑎′ = 7,2 − 3 × 0.1235 
𝑛 = 2 
𝑝𝐾𝑎 (H2PO4
− ↔ HPO4
2−)  = 7.2 
 
If I = 0.15M 
I = 0.1M  corr1 = 0.111 
I = 0.2 M  corr2 = 0.136 
I = 0.15 M  corr = 
𝑐𝑜𝑟𝑟1+𝑐𝑜𝑟𝑟2
2
 = 0.1235 
 
 Concentration of the solution: 
𝑝𝐻 = 𝑝𝐾𝑎′ + 𝑙𝑜𝑔
𝑎
𝑏
 
𝑎 + 𝑏 = 0.05𝑀 
a = acidic species (H2PO4-)   
b = basic species (HPO42-)   
 
Ionic force 
I =
1
2
 ∑ici × zi
2 
 
c – concentration of ionic species in solution 
z - charge of ionic species in solution 
 
To prepare phosphate buffer solutions with pH = 7,4, concentration of 0,05M and ionic force of 
0,15M, it was added to a volumetric flask: 
 2.65mL  of NaH2PO4 0.2M; 
 9.85mL of Na2HPO4 0.2M; 
 1.06mL of NaClO4 1M solution.  
 
The volume obtained was 13.65 mL and the total volume of 50 mL was reached with water.  
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Appendix I – 1H-NMR, 13C-NMR, HMQC, HMBC and APT structural analysis 
 
The followed spectras were performed in order to do the structural identification of the 
synthesized compounds. All the spectras were obtained in CDCl3.  
 
1H-NMR spectra of compound 2.  
 
1H-NMR spectra of compound 2.  
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13C-NMR spectra of compound 2. 
 
 
 
APT spectra of compound 2. 
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HMQC spectra of compound 2. 
 
HMBC spectra of compound 2. 
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Appendix II - Mobil phase used and retention time for each compound 
 
Compounds and retention times for a mobile phase of 50:50 (ACN:Water) 
Compound R Retention time/min 
2 C2H5 3.7 
3 C4H9 4.9 
4 C6H13 7.7 
3a C4H9 8.9 
 
 
Compounds and retention times for a mobile phase of 85:15 (ACN:Water) 
Compound R Retention time/min 
5 C9H19 3.8 
6 C10H21 4.0 
7 C11H23 4.3 
8 C12H25 4.7 
9 C14H29 6.4 
10 CH(CH3)C7H15 3.5 
5a C9H19 3.7 
6a C10H21 3.9 
7a C11H23 4.6 
8a C12H25 4.9 
9a C14H29 6.5 
10a CH(CH3)C7H15 3.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
